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Abstract 
Clostridium difficile infection (CDI) has proven to be a constantly evolving disease 
periodically posing new diagnostic and clinical dilemmas. Different regions of the 
world have reported specific local genomic characteristics of the infecting strains, 
which may be related to variation in disease presentation and outcome. This study 
was performed to determine the clinical and molecular features of severe, recurrent 
and community-associated disease in the Lothian region of Scotland, UK among 
patients diagnosed from August 2010-July 2011. Three hundred and thirty-five 
patients with laboratory confirmed CDI were studied for epidemiological features, 
clinical presentation, and laboratory markers. They were followed up for one year to 
determine recurrence and mortality. Four hundred and thirty-two episodes were 
recorded. Ribotypes, presence of toxin genes and MLVA subtypes of isolates from 
these episodes were determined. During the course of the study, PCR ribotype 078 
was identified as an important emerging type and concerns of “hypervirulence” were 
raised when an outbreak was recorded in 2012.  This ribotype was studied to 
compare its clinical and molecular characteristics with other endemic ribotypes and 
between its own outbreak-related and endemic subtypes. Asymptomatic children 
were also sampled to determine their role as pools of potential pathogens. 
Severe episodes accounted for 40.4% of total and 29.3% patients had multiple 
episodes on record. One-year mortality was 32.8% of which CDI was listed on 
25.5% death certificates. Ribotype 078 was confirmed in 6.8% episodes. 
Community-associated disease was identified in 25.3% patients, which differed 
significantly from hospital-associated disease in the number of antibiotics and 
gastrointestinal manipulation prior to CDI. Endemic PCR ribotype 078 caused 
significantly less recurrent disease and more community- associated disease when 
compared to the most prevalent ribotype 001. Patients who died from ribotype 078 
within 30d had a lower Charlson comorbidity index than ribotype 001 counterparts 
suggesting that the former may infect healthier patients. MLVA subtyping of 
ribotype 078 proved useful in identifying epidemiological relationships during the 
outbreak. CDI had contributed to the death of 50% of all patients infected with the 
outbreak related ribotype 078 strain compared to 14.3% of those infected with the 
 
 
   
vi 
endemic strains. This study documents the changing epidemiology of CDI in the 




  CA-CDI Community-associated CDI 
CCEY Cyclosine cefoxitiv egg-yolk agar 
CCI Charlson co-morbidity index 
CDI Clostridium difficile infection 
COPD Chronic obstructive pulmonary disease 
CRP C-reactive protein 
d Days 
DNA Deoxyribonucleic acid 
FAM Proprietary name 
GI Gastro-intestinal 
HA-CDI Hospital-associated CDI 
HCA-CDI Healthcare-associated CDI 
HCF Healthcare facility 
IBD Inflammatory bowel disease 
MIC Minimium inhibitory concentration 
MLST Multi-locus sequence typing 
MLVA Multi-locus variable number tandem repeat analysis 
MRSA Methicillin resistant Staphylococcus aureus 
NED Proprietary name 
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PCR Polymerase chain reaction 
PET Proprietary name 
PFGE Pulse field gel electrophoresis 
PMC Pseudomembranous colilits 
PPI Proton pump inhibitor 
RAPD Random amplified  
RNA Ribonucleic acid 
STRD Summed tandem repeat difference 
VIC Proprietary name 
VNTR Variable number tandem repeats 
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1.1 General microbiology 
1.1.1 C.difficile: A brief history 
The organism was first identified as a Gram-positive rod from the stool samples of 
babies in the year 1935, and  was difficult to grow under standard conditions. It was 
initially christened Bacillus difficilis (Hall and O'Toole, 1935) but was later re-named 
Clostridium difficile. However the clinical disease potential of this bacterium was 
confirmed even later in 1978 when experiments showed that the toxin produced in 
the faeces of patients with pseudomembranous colitis (PMC) and post operative 
diarrhoea was identical to the toxin of Clostridium difficile (George et al., 1978, 
Larson et al., 1978) 
Over the years, with better understanding of growth requirements, it has been fairly 
easy to cultivate under the right anaerobic conditions, but the exact pathogenesis still 
eludes us. Of its two anatomical forms, the vegetative form is known to be quite 
susceptible to antimicrobials and disinfectants, but once converted to the spore 
bearing form it can be quite resistant to common hospital disinfectants and as a result 
it persists in hospital environment as well as laboratory surfaces as demonstrated by 
numerous studies (Mayfield et al., 2000, Vohra and Poxton, 2011b, Kaatz et al., 
1988, Dumford et al., 2009). Its potential to cause outbreaks has been well 
documented (Hall et al., 1985, Barbut et al., 1994, Graf et al., 2009) though in the 
preceding few years the incidence has reportedly declined (HPA, 2012). However it 
remains endemic in many hospitals and its reported increase in incidence among the 
non- hospitalized community has been a subject of a substantial number of studies 
(Huang et al., 2009b, Fellmeth et al., 2010, Riley et al., 1986). It produces three 
toxins namely toxin A, toxin B which are strongly associated with symptomatic 
C.difficile infection (CDI) (Steele et al., 2012), and in addition a third toxin called the 
binary toxin is also produced in some strains with some studies suggesting its 
presence in severe cases of CDI (Barbut et al., 2005, Bacci et al., 2011). It is 
however, a multifactorial disease and factors such as use of antimicrobials, 
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administration of agents which reduce the production of stomach acid, multiple 
comorbidities, prolonged hospital admission and advanced age have been considered 
predisposing factors in various studies (Bloomfield et al., 2012).  
 
1.1.2  Characteristics of C.difficile   
C. difficile is a Gram-positive sporulating bacillus with an anaerobic lifestyle. It may, 
sometimes, appear Gram-variable. The cells are thin (0.5µm wide) and 3-5µm long. 
Spores, when present, are sub-terminally located. It grows well on enriched media 
like blood agar but clinical samples often necessitate the use of selective media due 
to the mixed flora of the sites where C. difficile generally inhabits. Cycloserine, 
cefoxitin, egg yolk (CCEY) agar is a commonly used medium. Colonies on CCEY 
are yellowish, flat, with an irregular edge and possess a ground glass appearance. On 
blood agar the colonies are non haemolytic 2-4mm in diameter, with a dull surface 
and a mottled appearance. C.difficile produces a distinctive unpleasant odour, which 
is likened to “horse manure”. 
1.1.3 Pathogenicity 
Pathogenicity of C. difficile is dependent on the presence of two high molecular 
weight toxins. Toxin A is a 308 kDa enterotoxin which increases fluid accumulation 
in ligated rabbit ileal loops and toxin B is a 270 kDa cytotoxin which produces 
cytopathic effects in tissue cultures. They both belong to the family of large 
clostridial cytotoxins (LCT) and their actions have been proposed to be synergistic 
(Rupnik et al., 2001). They both perform the function of glucosyltransferases and can 
inactivate the Rho, Rac and Cdc42 present in the intestinal cells. Some pathogenic 
strains are seen which elaborate toxin B but not toxin A (Toyokawa et al., 2003, 
Stabler et al., 2006).  The third toxin, called the binary toxin has also been found in 
6-15% strains (Voth and Ballard, 2005). Other virulence factors like adhesins and 
enzymes have been proposed but their role remains doubtful  (Poxton et al., 2001).  
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1.2 Clinical presentations 
1.2.1 Spectrum of infections 
CDI can present with mild self-limiting diarrhoea. However, it can also cause severe, 
life-threatening infection, which can be rapidly fatal. Between these two extremes  
there is a spectrum of more or less severe syndromes characterised by variable 
degrees of diarrhoea,   abdominal pain, fever and leucocytosis. Fulminant (or severe 
complicated) CDI is characterized by the presence of inflammatory lesions and 
pseudomembranes in the colon (giving it the name pseudomembranous colitis - 
PMC). Toxic megacolon may also occur leading to bowel perforation, sepsis, shock 
and death.  
However asymptomatic carriage can occur and studies have demonstrated 
colonisation rates varying from 4.2% to 15.3% in healthy non-hospitalised adults. 
Rates vary from the population studied (Kato et al., 2001). 
1.2.2 Severe infections 
Early identification of patients who are at high risk for severe CDI may help 
clinicians to alter the modifiable factors and hence improve outcomes.  For example 
surgical prophylaxis in high-risk patients may involve use of lower risk antibiotics. 
Various markers for severe disease have been proposed using variable end points. 
The commonest end point used is mortality up to 30d from diagnosis or development 
of toxic megacolon or pseudomembranous colitis.  Markers like total leucocyte 
count, serum albumin, serum creatinine and CRP have been studied.  Other risk 
factors like age, presence of co-morbidities, length of stay and immunosuppression 
have also been subjects of analysis and guidelines have been published on the 
identification and management of patients with severe CDI (HPA, 2008) However 
two recent systematic reviews have concluded that the studies published so far  have 
several potential limitations. The majority are retrospective employed single stage 
stool testing procedures, and some did not use multivariable analyses to adjust for 
confounders. Poor sample size and reliance on medical records can be additional 
limitations (Abou Chakra et al., 2012, Bloomfield et al., 2012). 
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1.2.3 Recurrent infections 
One of the characteristics features of C.difficile is its propensity to cause recurrent 
infections. Recurrences occur in 15 to 35% of cases (Fekety et al., 1997, Barbut et 
al., 2000). Recurrences of C. difficile-associated diarrhoea can be a serious clinical 
problem, increasing the length of stay and overall cost of hospitalisation (Spencer, 
1998). Patients may experience three or more episodes adding to their overall 
morbidity.   
The pathogenesis of recurrences may be explained either by the endogenous 
persistence of C. difficile spores or by the acquisition of a new strain from an 
exogenous source.  Reports have previously shown that 38 to 56% of recurrences of 
C. difficile-associated diseases were due to re-infections (Barbut et al., 2000). These 
numbers will no doubt vary with the discriminatory capacity of the technique used to 
determine strain type, since techniques like MLVA are known to be more 
discriminatory than ribotyping (van den Berg et al., 2007). 
The predisposition of patients to develop recurrent CDI has not yet been accurately 
determined, although a number of studies have investigated the subject. Some of 
these suffered from paucity of numbers and hence lacked the power to detect 
significant differences between recurrent and non-recurrent cases. A recent large-
scale population-based study has performed an analysis of the medical records of 363 
patients with clinical recurrence of CDI and proposed a score to predict CDI 
recurrence following first-ever CDI diagnosis. This score includes factors like 
severity of initial disease, past health care exposure, stool frequency, CRP level, age, 
previous MRSA colonisation, admission to a gastroenterology unit, etc. to determine 
the risk of development of a repeat episode of CDI. The score ranges from -2 to 15 
and the authors propose it can be used to make clinical decisions which would reduce 
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1.2.4 Place of acquisition 
Although the major burden of CDI lies in the hospitals, patients in the community are 
also at risk for CDI, albeit at a considerably lower rate than those who are 
hospitalised.  
Considering that healthy adults who had not been exposed to antimicrobial agents for 
the preceding four weeks, when examined for intestinal carriage of C. difficile, 
revealed an overall carriage rate of 7.6% by faecal culture and typing of their isolates 
by PCR ribotyping and pulsed-field gel electrophoresis (PFGE) demonstrated 
clusters of carriers colonised by a single type, it is very likely that community-
associated CDI can exist and even cross-transmit in close-knit groups (Kato et al., 
2001).  
The community-associated CDI rates in the United States have been reported as 7.7 
cases per 100,000 person years, and studies from the UK have reported community-
associated CDI prevalence of 1.29 per 10,000 population (Fellmeth et al., 2010).  
More recent studies by the Centre for Disease Control and Prevention found similar 
community rates, but an increased severity of the disease (Centers for Disease and 
Prevention, 2005, Centers for Disease and Prevention, 2008).  
Proposed sources of CDI in the community include soil, water, pets, animals used for 
food, meats, vegetables and salads (Bouttier et al., 2010, Gould and Limbago, 2010, 
Harvey et al., 2011, Keessen et al., 2011, Metcalf et al., 2010, Bakri et al., 2009a). 
However, even though strains related to human infection have been found from food-
related sources, causation of CDI from food and food products has never been 
proven.  Nevertheless there is an observed increase in rates of CDI, which could be 
due a variety of reasons including heightened awareness. Continuous vigilance and 
investigation may reveal hitherto unknown factors to connect the unknown pieces of 
the story.  
Although a number of good quality studies have recently been published 
characterising the factors associated with CA-CDI (Khanna et al., 2012c, Kuntz et 
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al., 2011), very few have evaluated the molecular epidemiology of the strains 
associated with CA-CDI. Hence this is an area where more information is needed.  
 
1.2.5 Predisposing factors  
1.2.5.1 Antibiotics 
Although 6-45% patients have been reported to develop CDI without known 
exposure to antibiotics (Fellmeth et al., 2010, Khanna et al., 2012c), the role of 
antibiotics in the aetiology of CDI has been established since many years.  
The aetiology of CDI following antibiotic exposure has been studied with the help of 
16S ribosomal RNA sequencing. The microflora of the gut is made up of a large 
number of microorganisms, which can be disrupted by the use of antibiotics. Since 
C. difficile can be resistant to a multitude of antibiotics, it can multiply unhindered in 
the intra-colonic environment made diversity-deficient by antibiotics. Recent studies 
have revealed that the effect of antibiotics on the microflora can last for several days 
even after the last dose of the offending antibiotic.  Susceptibility to CDI can persist 
for a variable amount of time depending on the half-life of the drug administered.   In 
a hamster model, clindamycin treatment led to a much longer period of susceptibility 
to infection as compared to cephalosporins (Merrigan et al., 2003b, Merrigan et al., 
2003a).  
In a recent multicentre case-control study from the Netherlands conducted between 
March 2006 and May 2009, 337 hospitalised patients with diarrhoea and a positive 
toxin test were compared with 337 patients without diarrhoea. A control group of 
patients with diarrhoea due to a cause other than CDI was also included.  Their 
results suggested that in the month prior to CDI, patients with symptoms more 
frequently used an antibiotic compared with non-diarrhoeal patients (77% versus 
49%). During antibiotic administration and in the first month after cessation of the 
therapy, patients had a 7-10-fold increased risk for CDI (OR 6.7-10.4). The highest 
risk for CDI was found during the first month after antibiotic use and this gradually 
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decreased from one month to three months after cessation of antibiotic therapy 
(Hensgens et al., 2012a).  
Restoration of colonisation resistance of the normal flora is therefore a key factor in 
the prevention of CDI in patients (Rupnik et al., 2009). Figure 1.1 explains the effect 
of antibiotics on the human gut and the resultant susceptibility to C. difficile. 
A recent study compared the efficacy of faecal transplantation with Vancomycin in 
the treatment for recurrent CDI and found that the Simpson's Reciprocal Index of 
diversity of fecal microbiota obtained from nine patients with recurrent CDI before 
faecal  transplantation was consistently low  and increased  after infusion to become 
comparable with that of the donors.    
In addition phylogenetic microarray profiles of each sample  showed that after 
donor-faeces infusion there were quantitative changes in relevant groups of intestinal 
bacteria (P<0.05) and included  xincluded increased numbers of Bacteroidetes 
species and of clostridium clusters IV and XIVa  and decreased numbers of 










Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
10 
Figure	  1.1	  Effects	  of	  antibiotics	  on	  gut	  flora	  
 
Figure adapted from Maja Rupnik, Mark H. Wilcox & Dale N. Gerding Clostridium difficile 
infection: new developments in epidemiology and pathogenesis Nature Reviews Microbiology 7, 
526-536 (July 2009) 
(a) Resistant to CDI in the absence of antibiotics. 
(b) During antibiotic treatment C. difficile  can overgrow in the absence of competing normal 
flora, since it is likely to be resistant to the antibiotic being administered 
(c) Once the antibiotic stops, the microflora remains disturbed for a variable period of time 
(indicated by the break in the graph), depending on the antibiotic given, hence 
susceptibility to antibiotics remains even after cessation of the offending antibiotic. During 
this time, patients can be infected with either resistant or susceptible C. difficile.  
(d)  Colonisation resistance to C. difficile is restored once the normal microbiota regenerates 
 
Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
11 
 
1.2.5.2 Age and gender 
 C. difficile infection mostly affects the elderly population, although cases are being 
seen in younger patients including children and pregnant women (Hojsak et al., 
2012). Children reported to develop CDI usually have predisposing factors like 
immunosuppression and malignant disease, and exposure to multiple antibiotics 
classes (Kim et al., 2012). 
However the burden of infection lies in the ageing population. Studies evaluating risk 
factors have suggested that increasing age >75 are associated with the development 
of recurrent or severe disease (Eyre et al., 2012). Data is accumulating that 
community-associated disease may affect a younger population  
An evaluation in an urban, tertiary care hospital of 89 CDI inpatients divided by age  
< 60 yr of age (younger) and those > or = 60 yr (elderly) identified no difference in 
mortality or morbidity in elderly individuals with CDI when compared with younger 
persons with CDI. The response to standard treatment was similar in both groups. 
However, the elderly patients were more likely to have an elevated total leucocyte 
count (60% vs. 26%, p < 0.05), and were more likely to have hospital-associated 
disease (89% vs. 50%, p < 0.0001)(Brandt et al., 1999). 
However another study found age over 70 years, co-morbid illness and CDI 
recurrence as significant risk factors for severe disease and a poor outcome (Andrews 
et al., 2003). 
Hence there are mixed reports on the effects of age on CDI recurrence severity and 
mortality. Gender differences have only rarely if ever been reported. 
1.2.5.3 Acid suppressing agents 
In the normal human stomach, the low pH due to normal gastric acid secretion acts 
an as defence against microorganisms which may enter the body via the mouth. 
Inhibition of this gastric acid removes this innate immune mechanism against 
ingested bacteria and spores, increasing the risk of some forms of gastroenteritis. 
Hence it is suggested that gastric acid suppression may also increase the risk of CDI. 
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A number of studies have investigated a possible link between acid suppression 
therapy and CDI in various patient populations but have reported conflicting results. 
In a report of two communities population based case control studies in the United 
Kingdom the first included 1672 cases of CDI between 1994 and 2004. Each case 
was matched to 10 controls.  In the second study community-associated cases were 
matched to non-hospitalised controls. The adjusted rate ratio of CDI with current use 
of proton pump inhibitors was 2.9 (95% CI 2.4-3.4) and with H2-receptor antagonists 
the rate ratio was 2.0 (95% CI, 1.6-2.7, hence concluding that the use of acid-
suppressive therapy was associated with an increased risk of CA-CDI (Dial et al., 
2005). 
Another population-based, nested case-control study of linked health care databases 
in Canada, from 1 April 2002 through 31 March 2005 identified patients ≥ 66 years 
of age who were hospitalized for CDI within 60 days of antibiotic administration in 
the community. One thousand three hundred and eighty-nine case patients were 
matched with 12,303 control subjects. PPI use by case patients and control subjects 
was categorized as current (within 90 days), recent (91-180 days), or remote (181-
365 days). Case patients were found to be no more likely than control subjects to 
have received a PPI in the preceding 90 days (AOR 0.9; 95% CI 0.8-1.1). No 
association between hospitalization for CDI and more remote use of PPIs was found 
(Lowe et al., 2006).  
A more recent report compared the outcomes of patients with CDI to establish an 
association with PPI use. Demographic data and outcomes, including severe, severe-
complicated, and recurrent CDI and treatment failure were compared in a cohort of 
patients with CDI who were treated with acid suppression medications with these 
outcomes in a cohort with CDI that was not exposed to acid-suppressing agents.  On 
univariate analysis, patients taking acid suppression medications were significantly 
older (69 vs 56 years; P<.001) and more likely to have severe (34.2% vs 23.6%; 
P=0.03) or severe-complicated (4.4% vs 2.6% CDI; P=.006) infection than patients 
not undergoing acid suppression. On multivariable analyses, after adjustment for age 
and co-morbid conditions, acid suppression medication use was not associated with 
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severe or severe-complicated CDI. In addition, no association between acid 
suppression and treatment failure or CDI recurrence was found. Hence patients on 
acid suppression treatment were not more likely to experience severe or severe-
complicated CDI, treatment failure, or recurrent infection (Khanna et al., 2012a). 
From the above studies it seems that there is yet no conclusive evidence on the effect 
of acid suppressive medication and the incidence and severity of CDI. 
1.2.5.4 Colonisation with other hospital acquired pathogens 
There have been reports of association of CDI with other primarily hospital 
associated pathogens like MRSA and VRE carriage. A study evaluating the risk 
factors for CDI and VRE found that antimicrobial exposure, number of 
antimicrobials, days of antimicrobial use, third-generation cephalosporins, 
clindamycin, patient age, length of admission, severity of underlying illness, enteral 
feedings, environmental contamination, and contamination of the hands of health 
care workers were associated with their carriage (Gerding, 1997). 
A recent report found that patients with CDI were more likely to be colonised with 
MRSA in medical wards as compared to surgical wards (Lavan et al., 2012).  
Since these pathogens share risk factors with CDI acquisition, it is possible that they 
could contribute to a risk evaluation assessment of patients who are likely to develop 
CDI or its complications. 
1.2.5.5 Underlying GI pathology 
Underlying gastro-intestinal pathology including inflammatory bowel disease, cancer 
of the GI tract, and other structural and physiological abnormalities have been known 
to disrupt the normal functioning of the gut and hence could pose an increased risk 
for the development of CDI. A number of studies have tried to evaluate this risk but 
no conclusive evidence has yet been found.   
In some previous studies, no statistically significant association was found between 
complications and history of bowel surgery (Morrison et al., 2011) or enteral feeding. 
However, at least one study found small bowel obstruction as a significant risk factor 
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on multivariable analysis (OR 3.33, p value 0.014)(Henrich et al., 2009). Another 
case control study involving 35 patients with fulminant CDI, found operative therapy 
within the last 30 days (P = .03) and a history of inflammatory bowel disease (P = 
0.04) independent risk factors for the development of fulminant CDI on multivariate 
analysis (Greenstein et al., 2008).  
1.2.5.6 Immunosuppression 
As the factors already mentioned, immunosuppression has been studied in various 
aetiological studies. However, the definition of immunosuppression varies from 
study to study, hence a general comparison cannot be made between studies. 
However, immunosuppression was one of the factors that predisposed to the 
development of severe C. difficile colitis (p< 0.05) in a study compare risk factors for 
severe colitis (Rubin et al., 1995).  
An evaluation of the prevalence of risk factors treatment and outcome of CDI in 
patients with human immunodeficiency virus (HIV) infection including 124 patients 
grouped as HIV-infected with CDI, HIV-seronegative patients with CDI and HIV-
infected patients without CDI revealed that the prevalence of CDI in HIV-infected 
patients was more than in HIV-seronegative patients (P = 0.02). The clinical 
symptoms of CDI were more severe in HIV-infected patients than in controls, though 
the CD4+ cells did not influence the outcome of CDI. No difference in the survival 
curves of AIDS patients with or without CDI, stratified according to age, sex and 
CD4+ cell count was observed (Tumbarello et al., 1995).  
Another study defined immunosuppression as presence of human immunodeficiency 
virus (HIV), leukaemia, lymphoma, organ transplant, neutropenia, 
immunosuppressive drug use or systemic corticosteroids for >1 month and found a 
statistically significant correlation with severity of CDI (OR 2.7; 95% CI 1.5, 4.9) 
(Pepin et al., 2007). However a number of other studies did not find a statistical 
correlation (Gujja and Friedenberg, 2009, Labbe et al., 2008, Morris et al., 2002). 
Of note, the markers of severity appear to be different between immunosuppressed 
and immunocompetent patients as suggested by a recent study, which evaluated 29 
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immunosuppressed patients with CDI. The white blood cell count, platelet, and 
albumin levels were found to be the same in the severe and non-severe 
immunosuppressed CDI patients although those with severe CDI were older and had 
evidence of renal dysfunction (Pant et al., 2011) 
1.2.5.7 Analysis of co-morbidities 
A number of co-morbid conditions like renal disease, gastrointestinal conditions, 
COPD, diabetes and cancer have been individually studied as predisposing 
conditions for severe and/or recurrent disease. However the commonest marker used 
for analysing the co-morbid condition has been the Charlson co-morbidity index 
(CCI) 
Although other co-morbidity indices are available (Index of co-existent disease, 
geriatric index of co-morbidity, functional co-morbidity index, total illness burden 
index) none appears to be distinctly superior to others. Since Charlson Index was 
consistently associated with outcome it has been used in a number of studies 
reporting CDI related research.  
The Charlson Index was proposed in 1987 as a means for quantifying the prognosis 
of patients enrolled in clinical trials (Charlson et al., 1987). It was based on one-year 
mortality data from internal medicine patients admitted to a single New York 
Hospital and was initially validated within a cohort of breast cancer patients. The 
index encompasses 19 medical conditions weighted 1–6 with total scores ranging 
from 0–37.  When it was being developed, a stepwise backward proportional hazards 
Cox Regression model was used to calculate the relative hazard of patients with the 
co-morbidity to a relative risk of death within 12 months. A weight was then 
assigned to each condition based on the relative risk (RR); for example, RR <1.2 = 
weight 0, RR 1.2<1.5 = weight 1, RR 1.5<2.5 = weight 2, RR 2.5<3.5 = weight 3, 
and for 2 conditions (metastatic solid tumour and AIDS) = weight 6 
 Criticism for the use of the CCI is that it was developed as a research tool using a 
variety of different conditions and hence its applicability in routine practice is likely 
to be cumbersome. Also it includes only 19 conditions, so there may be others 
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associated with the risk of dying which are not included. Nevertheless the CCI has 
been consistently associated with severity due to CDI (Bloomfield et al., 2012). 
1.3 Disease in children 
Although paediatric disease has been reported since the 1980s, it has been a 
relatively recent area of interest.  
1.3.1 Theories for low pathogenicity 
 The low incidence of CDI in children has been observed since many years though 
recent studies are reporting an increase in incidence. Proposed theories for the low 
paediatric incidence include absence of toxin receptors in the neonatal gut and 
neutralisation by colostrum (Wolfhagen et al., 1994). However none of these have 
been substantiated and the structure of the receptors to C. difficile toxins A and B is 
still not defined.  
1.3.2 Incidence 
Studies have reported that CDI in children is a real and increasing problem. The 
annual rate of paediatric hospitalisations with CDI in the United States was reported 
to increase from 7.24 to 12.80 cases/10,000 hospitalisations  from 1997 through 
2006.  Although incidence was lowest for newborns (0.5 cases/10,000 
hospitalizations), incidence for children <1 year of age who were not newborns 
(32.01 cases/10,000 hospitalisations) was similar to that for children 5-9 years of age 
(35.27 cases/10,000 hospitalisations) (Zilberberg et al., 2010) 
In addition, the CDI rate has been reported to be up to 15 times more among children 
with cancer compared with those without cancer. Children with cancer accounted for 
21% of all paediatric CDI cases (Tai et al., 2011). 
1.3.3 Pool of potential pathogens 
In addition to increasing incidence of disease, theories have been proposed on the 
possible link between asymptomatic carriage in children and the maintenance of a 
pool of potential pathogens in the community (Rousseau et al., 2012)  since at least 
some studies have reported that the presence of C. difficile in stools of children even 
after antibiotic therapy may not significantly associated with the onset of antibiotic-
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associated diarrhoea (Elstner et al., 1983). Although the transmission of C. difficile 
from children to adults has however never been proven, molecular typing of 28 C. 
difficile isolates from children in Oxfordshire, United Kingdom, identified eight 
toxigenic genotypes, of which six were also found in 83 (27%) concurrent adult CDI 
cases, suggesting that children could transmit of some adult disease-causing 
genotypes (Stoesser et al., 2011). 
1.4 Laboratory diagnosis 
The laboratory diagnosis of CDI is generally made by non-culture techniques, they 
being less labour intensive than culture. Direct toxin detection from stool is 
considered the most convenient method, as the presence of toxin is a prerequisite to 
confirm the pathogenicity of the strain. Culture based methods, if used, must then 
also go through a toxin detection ritual if pathogenicity is to be established.  
Toxin detection by the tissue culture cytotoxin assay is often regarded as the gold 
standard but currently the most common technique is enzyme immunoassay (EIA). 
Earlier EIA kits performed only toxin A detection but after the pathogenic potential 
of A-B+ C.difficile strains was established, kits using a combination of toxin A and 
toxin B detection are routinely used.  More recently direct PCR from the stool 
sample to detect the toxin gene has been found to have a greater sensitivity than toxin 
EIA. A study recent reported that 44% of all cases were detected by PCR only as 
opposed to cytotoxin assay, and the proportion of cases of non ribotype 027 detected 
by PCR only differed significantly from patients infected with ribotype 027 strains (P 
< 0.05). However no significant difference was found in the severity of illness and 
outcome among patients that tested positive for CDI by both tests compared to those 
that tested positive by PCR only (Kaltsas et al., 2012).  
Glutamate dehydrogenase (GDH), encoded by the gluD gene, is a metabolic enzyme 
produced by C. difficile. It is known to be present in the stool sample of patients 
infected with C. difficile and has been used as a marker for the presence of 
C.difficile. However since it is present in both toxigenic and non-toxigenic strains, 
the detection of GDH must be followed up with a more specific test like toxin EIA to 
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detect direct toxin  or PCR to detect the toxin gene. GDH has been found to be 
highly conserved among C. difficile ribotypes (Carman et al., 2012). 
The two-stage algorithm toxin EIA/PCR was more specific compared to the 
GDH/PCR combination when compared with either of the two reference tests cell 
cytotoxin and cytotoxigenic culture reference methods. However the latter was more 
sensitive. The PPV for the toxin EIA-based algorithm was higher (89.0-90.8%) than 
the GDH based algorithm (59.6-80.7%) (Wilcox and Planche, 2011).  
 At the present time, there is considerable diversity in the practice of laboratory 
diagnosis of CDI. A multi-step approach to diagnosis using either GDH and EIA 
combination or GDH EIA/ toxin gene PCR culture combination algorithm is 
recommended (Wilcox et al., 2010). 
1.4.1 Antimicrobial susceptibility 
Traditionally anaerobes have been considered susceptible to metronidazole. Practice 
guidelines recommend metronidazole or vancomycin as first line therapy (HPA, 
2008). However, in a study comprising 632 infected cases treated with 
metronidazole, failure of therapy was reported in 14 (2%) cases (Sanchez et al, 
1999). Recent reports of metronidazole resistance state that 2-6% isolates may have 
an MIC greater than the susceptible breakpoint of 16µg ml-1  (Bishara et al., 2006, 
Brazier et al., 2001, Johnson et al., 2000). A recent report  examined the genome of 
C.difficile  strain stably resistant to metronidazole by whole genome sequencing and 
comparative genomic analysis and found single nucleotide polymorphism (SNP) 
level variation within genes affecting core metabolic pathways such as electron 
transport, iron utilization and energy production (Lynch et al., 2013) 
1.5 Molecular biology 
After the genome of the C. difficile strain 630 was sequenced, the results facilitated a 
good understanding of the molecular structure of the organism (Sebaihia et al., 
2006). Although belonging to the genus Clostridium, the genome of C. difficile 
shares only 15% of its coding sequences (CDSs) with other clostridia like C. 
perfringens, C. tetani and C. botulinum. About 50% of its CDSs are unique to itself. 
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Its G+C content is extremely variable throughout its length probably because of a 
number of mobile genetic elements, which comprise about 11% of its genome. The 
C. difficile genome possesses an element closely related to the conjugative 
transposon Tn916 that mediates tetracycline resistance. Other transposons, which 
occupy places, are CTn2, CTn4 and CTn5, which are related to the vancomycin 
resistance coding transposon Tn1549. However resistance studies revealed that 
although present these do not encode vancomycin resistance in the organism.  
More recently the genomes of other pathogenic ribotypes have been sequenced and 
data regarding the differences between strains is emerging. Whole genome 
sequencing was used in one study to genetic variation and virulence among 30 
different C. difficile isolates, to determine macro and microevolution of the species. 
According to their results it appears that horizontal gene transfer and large-scale 
recombination of core genes has been involved in the recent and distant evolution of 
C. difficile. Many lineages appear to co-exist in pathogenic C. difficile suggesting 
that virulence evolved independently (He et al., 2010). 
1.5.1 Virulence factors 
The virulence factors are coded on a pathogenicity island called Pathogenicity Locus 
(PaLoc). Five genes are present in this region viz. tcdA,B,C,R & E responsible for the 
production and regulation of the virulence factors toxin A (TcdA) and toxin B 
(TcdB). The TcdC is a negative regulator of toxin production as inferred by its high 
expression during the early phase of growth when toxin production is minimal and 
decrease in the stationary phase when toxin production accelerates. TcdR bears 
considerable homology with other known toxin positive regulators TetR in 
Clostridium tetanus and BotR present in Clostridium botulinum. It is expressed co-
ordinately with TcdA and TcdB and experimental studies suggest that it can enhance 
the expression of promoter-reporter fusions of the in C. difficile toxins (Moncrief et 
al., 1997). TcdE, is a protein resembling the holin proteins and may enable release of 
the toxins from the cells (Tan et al., 2001). 
Although some pathogenic strains are known to lack TcdA, strain 630 produces both 
TcdA and TcdB. Some strains of C. difficile produce a third toxin called binary toxin 
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with two components: CdtA and CdtB. However, cdtA and cdtB are mere 
pseudogenes in strain 630. In non-toxigenic strains the PaLoc is replaced by a region 
of 115 bases (Rupnik et al., 1998).  
Outside the cell wall of this organism, there is a complex paracrystalline array of 
proteins termed the S layer. This is composed of two proteins, which are coded by a 
single gene slpA. The higher molecular weight surface layer protein (SLP) is highly 
conserved among the strains, whereas the lower molecular weight SLP shows 
considerable sequence diversity. C. difficile is unique in that it produces two surface 
proteins distinct from each other but both are products of the same gene. The 
removal of peptides and a cleavage event occur in the post translational phase to 
produce the two separate proteins (Calabri et al, 2001)  Since  there are 28 paralogs 
of this gene and each contain multiple copies of Pfam (cell wall binding) motif 
PF04122, this property is being used to develop a separate typing scheme (Kato et 
al., 2005).  
The whole genome sequence analysis also revealed several CDSs which resemble 
antibiotic resistance elements. The expression of these was tested by phenotypic 
means and it was found that of the predicted resistances, the organism was resistant 
to agents like tetracycline, erythromycin and daunorubicin, bacitracin, and 
nogalmycin but sensitive to vancomycin and teicoplanin. 
1.5.1.1 Genes associated with toxin production and the pathogenicity 
locus (PaLoc) 
Other genes present on the PaLoc are tcdR, tcdE and tcdC of which the last is a 
putative negative regulator of tcdA and tcdB (Rupnik et al., 2005). Since strains 
which do not produce either of these toxins are not associated with pathogenicity, 
diagnosis of CDI is based largely on the demonstration of toxins either directly form 
stool samples or by toxigenic culture. For the former traditional methods like ELISA   
have been used.  
Studies have demonstrated various modifications of the PaLoc region which include  
• deletions in the  3’-end of  tcdA which result in non detectable levels of TcdA 
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• internal deletions and premature stop codons in  tcdC with the potential to 
produce an inactive gene product 
• polymorphisms in the PaLoc region which have been identified into 24 
profile by PCR restriction fragment length polymorphism (RFLP) 
1.6 Epidemiological typing  
In an event of an increase in incidence of the disease it becomes important to 
ascertain whether there is a common source of the pathogen or if there is a loss of 
adequate infection control precautions enabling increased transmission. Since it is a 
coloniser in the gut, it is important to note whether the increased incidence is 
secondary to uncontrollable causes like patients’ general condition and co-
morbidities or whether it is due to increased transmission, a potentially controllable 
cause. In addition to this epidemiological typing can provide an indication as to 
whether an outbreak is associated with a strain associated with enhanced 
pathogenicity like the PCR ribotype 027. It can also be used to examine changes in 
circulating types over time. 
1.6.1 Typing methods in use 
In the past many methods of epidemiological typing have been employed germane to 
the molecular understanding at the given time. Antibiograms, bacteriocin and 
bacteriophage typing, sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PAGE), serotyping, pyrolysis mass spectrometry, plasmid profiling, restriction 
endonuclease analysis, toxinotyping with restriction fragment length polymorphism, 
and arbitrary primed PCR have all been used with varying degrees of success 
(Tabaqchali et al., 1984, Delmee et al., 1985, Wren and Tabaqchali, 1987, Dei, 1989, 
McKay et al., 1989). However, over the years, practical application of each method 
has been concurred by its ease of use, inter laboratory comparability, cost and 
discrimination capacity. In the early 2000s, the methods employed in North America 
were pulsed field gel electrophoresis (PFGE) whereas most of Europe was using 
PCR ribotyping. More recently the reference laboratories in the UK are still using 
PCR ribotyping routinely with the addition of more discriminatory methods like 
multilocus variable number tandem repeat analysis (MLVA), which has been shown 
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to differentiate between ribotypes (van den Berg et al., 2007).  The routine use of 
sequencers and specialized software has made the application of these techniques 
easier over time. More recently, with whole genome sequencing becoming an 
application with potential to provide real time epidemiological answers in the event 
of outbreaks, this may be the technique used more widely in the future (Singh et al., 
2012) 
1.6.1.1 PCR ribotyping 
This technique uses variability in the intergenic spacer regions between the 16s and 
23s RNA regions to differentiate between strain types. The method described by 
O’Neill et al (1998) was in use for a considerable length of time but had the 
disadvantages of needing a very stringent protocol for gel electrophoresis and a 
comprehensive database to compare strain types. In addition, comparison had a 
human visual component subject to user dependent error. This technique was further 
modified to enable more specific band discrimination using objective comparison by 
specialized software. Although the comparison still has a visual component and a 
database is required to compare the band patterns, the end result has the advantage of 
being more specific.  
1.6.2 Subtyping methods  
1.6.2.1 MLVA 
This technique involves the amplification of multiple genomic loci where there are 
known VNTRs using PCR and establishing a MLVA type based on the number of 
repeat sequences found in each locus. Typically each repeat sequence was short, 
around 4-15 base pairs in length. It was first used as a typing method for C. difficile 
by March et al (2006) where they amplified seven loci to discriminate between 
(ribotypes/PFGE types). Subsequently this method also used by van den Berg et al 
(2007) with a slightly different combination of loci and primers although the total 
number of loci studied were still seven. It was found that ribotypes 027 and 001,   
could be subtyped into smaller groups by MLVA. This technique was further 
modified with the addition of eight loci to establish the extended MLVA scheme 
(eMLVA) (Manzoor et al., 2011). The additional loci were larger (up to 75 bp in 
length) than those previously used. Cluster analysis of the strains they studied 
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grouped all ribotypes together while enabling subtyping. Hence this method was 
advertised as a possible substitute to ribotyping. They simplified the technique by 
using capillary gel electrophoresis using four different fluorescent dyes in each well 
to enable four loci to be analysed simultaneously in each well of a 98 well microtitre 
plate. Analysis of the copy numbers was further automated by the formation of 
panels, which could be read by GeneMapper software. However since the number of 
ribotypes used in their study was limited, there was insufficient evidence to say 
whether it can be used as an alternative to ribotyping 
1.6.2.2 Whole genome microarray analysis 
This state-of-the-art whole genome analysis technique involves production of 
microarrays comprising DNA motifs from various genes of a fully sequenced strain.   
PCR amplified genes of test strains are compared by hybridisation with the DNA of 
the standard strain on glass chips. This technology has been recently applied to 
analyse 75 ecologically and clinically diverse C. difficile isolates. Using 
mathematical modelling and microarray data set the isolates could be grouped into 4 
clades differentiating the toxin A deficient, hypervirulent and animal and human 
isolates.  This technology is very demanding and expensive for routine studies but 
appears to be highly precise for advanced phylogenetic analysis.    
1.6.2.3 MLST 
MLST has been found to have similar discriminatory abilities as ribotyping indices 
of discrimination of 0.90 and 0.92, respectively. Some STs correspond to a single 
PCR ribotype (32 of the 40 studied isolates); other STs corresponded to multiple 
PCR ribotypes (8/40). Hence the PCR ribotype was not always predictive of the ST 
(Griffiths et al., 2010). 
1.6.2.4 Whole genome sequencing (WGS) 
This technology offers the greatest insight into the genomic structure of the 
organisms. Novel virulence factor encoding genes may be recognised by comparing 
different strains of the same species (Belkum, 2002). It also provides a model for the 
study of genetic variations (Spencer et al, 2003). However, the time and expense that 
used to be involved in applying whole genome sequencing as a routine 
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epidemiological procedure used to make it impractical technique for routine use. 
However advances in technology are changing that and whole genome sequencing 
has been used in a few studies to provide real time answers in with the right 
infrastructure could be used to identify outbreaks (Koser et al., 2012). 
1.7 Molecular epidemiology   
1.7.1 Geographical diversity and evolution  
In 2005, a strain responsible for a large number of infections in hospitals across 
North America  was identified as  PCR ribotype 027 . This type was characterized as 
group BI by restriction endonuclease analysis (REA), as North American pulsed-
field type NAP1 by pulsed-field gel electrophoresis (PFGE).  Since then, this 
ribotype has been involved in a number of outbreaks in the US and Europe including 
the UK.  
Rising rates of CDI in the past decade have been documented (Tan et al., 2007) and 
thought to be largely due to this strain although increased awareness, and a larger 
susceptible population no doubt play a role as well.   Other strains of C .difficile are 
also found with varying prevalence depending on the geographical location. 
Outbreaks are not limited to PCR ribotype 027 and have been associated with many 
others including ribotype 106, 078, and 017 (Ratnayake et al., 2011, Goorhuis et al., 
2011, Balassiano et al., 2011)  
 The prevalence of C. difficile ribotype 078 has increased recently from 3% to 13% 
in several countries in Europe (Goorhuis et al., 2008b, Burns et al., 2010, Goorhuis et 
al., 2008a). In the Netherlands, patients infected with ribotype 078 were younger 
(67.4 versus 73.5 years) and had community-associated disease more frequently 
(17.5% versus 6.7%; odds ratio = 2.98; 95% confidence interval = 2.11–8.02) than 
patients infected with ribotype 027 (Goorhuis et al., 2008a)  
1.7.2 PCR Ribotypes in south-east Scotland 
 A collection of 179 isolates of C. difficile obtained from symptomatic adult patients 
in southern Scotland between 1979 and 2004 identified 56 different ribotypes of 
which ribotype 002 was the commonest, followed by ribotypes 014, 012, 015, 020 
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and 001. Ribotype 001 increased in prevalence from 1.5 to 12.2 % over the study 
years, whereas the prevalence of ribotype 012 decreased from 8.7 to 2 .0%. Ribotype 
078 was also identified (Taori et al., 2010).  
From all Scottish health boards PCR ribotypes106 (29.4%), ribotype 001 (22%) and 
ribotype 027 (12.6%) were the commonest between November 2007 and December 
2009, followed by the less prevalent ribotypes including 002, 015, 014, 078, 005, 023 
and 020. The predominant isolates varied between regions (Wiuff et al., 2011). 
The most recent report by Health Protection Scotland suggests that ribotype 078 is 
the most common ribotype (28%) isolated among the 156 cases analysed in the 
clinical surveillance (severe cases and outbreaks) and 89 cases (21% of type 078) 
from the representative surveillance. 
The proportion of ribotype 078 among isolates from severe cases/outbreaks has 
increased from 2.5% in 2008 to 3.2% in 2009, 4.3% in 2010 and 7.8% in 2011and 
almost comparably from the representative surveillance. Hence although it has been 
reported since the mid 1990s, its prevalence has increased substantially in the past 5 
years. Whereas the other ribotypes 106, 001 and 027 have become comparatively 
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To determine the incidence and characteristics of CDI acquired from community 
sources 
To study the incidence, clinical features and molecular characteristics of severe and 
recurrent CDI 
To compare the emerging C. difficile ribotype 078 with other prevalent ribotypes and 
determine clinical and molecular differences between its endemic and outbreak-
associated strains  
To examine the incidence of C.difficile in asymptomatic children with a view to 
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Chapter 2  
Materials and Methods 
2  




Stool samples included in this study for aims 1-3 were sent to the diagnostic lab 
without interference by the researchers. After discussion with the University of 
Edinburgh and NHS Lothian Research and Development Department, Caldicott 
approval was sought for access to their names, dates of birth, CHI numbers, GP 
contact details and hospital notes.  
For aim 4, ethics clearance was obtained from the NHS/RHSC Research and 
Development offices and Research Ethics Committee for collection of stool samples. 
2.1.2 Consent 
Information sheets were given and written informed consent was sought from parents 
(see appendix 3). Children of parents who provided consent were included in the 
study. 
2.2 Patient inclusion  
2.2.1 General study 
Patients whose stool samples were sent to the Royal Infirmary of Edinburgh 
Microbiology laboratory and which tested positive for C. difficile toxin (A and/or B) 
by EIA and glutamate dehydrogenase (GDH) was included in study from the time the 
sample tested positive. These patients were prospectively followed up for one year 
after the first stool sample tested positive. 
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2.2.2 Paediatric colonisation study 
Neonates admitted to the neonatal unit over a four-week period from 7th August to 3rd 
September 2010 were eligible for inclusion in the study.  If consent was obtained 
from parents, those children were included in the study.  
The children at the crèche at The Royal Hospital for Sick Children (RHSC) were 
sampled between 1st and 15th October 2011. Similar to the neonatal unit, those 
children whose parents provided consent were included.   
2.3 Sample collection 
2.3.1 General study  
Attending clinicians based on the clinical symptoms and history of each patient 
requisitioned these samples. The staff collected them from the ward of admission. 
According to the Department of Heath guidelines repeat samples are generally not 
tested within 28d of a previous toxin positive stool. However they are often tested if 
a repeat sample is not identified, or if a clinician specially requests them for clinical 
reasons. 
2.3.2 Paediatric colonisation study 
Samples were collected by the attending nurses in the neonatal unit twice per week 
for four weeks and by the babysitters at the RHSC crèche as a one off sample per 
child. Parents collected samples at home if the child did not pass stool while at the 
crèche.   
2.4 Confidentiality and storage 
2.4.1 Confidentiality 
All stool samples were linked with a confidential number made unidentifiable at the 
point of collection (either ward or clinical laboratory) before being brought to the 
research laboratory. A note was made of the patients’ name, date of birth and sample 
number and this was stored confidentially. Each patient was given a new patient 
number and each sample was given a new sample number.  All confidential 
information was stored on password protected NHS Lothian computers or 
confidential cupboard in the microbiology department. 
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2.4.2 Sample storage 
Stool samples were cultured on CCEY medium and isolates stored in cooked meat 
broth. The remaining stool samples were stored at -20°C in the research lab. They 
were later used for DNA extraction and PCR for Norovirus. 
2.5 Data collection 
2.5.1 Follow up and data collection 
Initial patient data was collected by personal visit to the ward of admission or by 
telephone contact with the attending ward doctor or the GP requesting the test. 
Follow up was performed at two weeks and on year by telephone contact with the 
ward doctors if the patient was still admitted or by reviewing written records on 
Lothian hospitals IT system (trak) and by telephone contact with the GP with whom 
the patient was registered. Recovery, recurrence, change of treatment, discharge and 
or death was recorded (see appendix 1) The Charlson Co-morbidity Index was 
calculated using a macro enabled Excel tool available online (Hall et al., 2004), see 
appendix 2.  
Co-morbidities were determined by reviewing written records and by telephone 
conversation with GPs. Haematological and biochemical data was obtained from the 
Lothian hospitals IT system.  
Mortality data and information on death certificates was obtained from the NHS 
Lothian Public Health Department. 
2.6 Culture for C. difficile   
All stool samples were cultured on pre-reduced CCEY agar plates after alcohol 
shock (see appendix 4). For the neonatal samples, an additional blood agar plate was 
also cultured without alcohol shock. The plates were incubated in an anaerobic 
cabinet for 48 hours after which they were examined for colonies resembling 
Clostridium difficile. Such colonies were subjected to fluorescent lamp to look for 
the characteristic green fluorescence. A single colony was then plated onto pre-
reduced BA. After a further incubation of 24-48h, the colonies were examined for 
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characteristic smell and inoculated into Robertson’s cooked meat broth for storage 
till further testing. All isolates were later subjected to toxin A and toxin B PCR to 
confirm identification. A known culture positive stool was included as a positive 
control with every batch of culture. 
2.7 PCR ribotyping 
2.7.1 Isolates  
Stock cultures from cooked meat medium were sub-cultured onto CCEY and 
incubated anaerobically for 48h. A single colony was plated on BA and incubated for 
24h-48h. All C. difficile isolates obtained were subjected to PCR ribotyping and 
toxin gene PCR as below.  
2.7.2 DNA template preparation 
All DNA templates were prepared by the Chelex DNA extraction method (Stubbs et 
al., 1999). A 1% Chelex suspension (0.1µg per 100µl) was prepared and dispensed in 
an Eppendorf tube in aliquots of 100µl. A 1µl loop was used to scrape colonies off 
the BA and this was suspended into the Chelex. This suspension was vortexed for a 
few min before placing in a 100°C heat block for 10 min. The heated suspension was 
again vortexed briefly and then centrifuged for 10 min. The supernatant was used as 
the template DNA. This was either used immediately in the PCR mix or aliquoted 
into fresh tubes and stored at 4°C for max of 3 days before use. A small aliquot of 
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2.7.3 Primers and reaction volumes 
	  Table	  1.1	  	  Primer	  sequences	  used	  in	  ribotyping	  and	  toxin	  analysis	  
Gene 
segment 
Primer sequence with fluorescent label used Reference 
Ribo F 5'- PET - CTGGGGTGAAGTCGTAACAAGG O’Neill et al 1996 
R 5' - GCGCCCTTTGTAGCTTGACC O’Neill et al 1996 
tcdA             
                     
F 5' - FAM - 
GCATGATAAGGCAACTTCAGTGGTA 
Perssons et al 2011 
R 5' - AGTTCCTCCTGCTCCATCAAATG Perssons et al 2011 
tcdB F 5' - FAM - 
CCAAARTGGAGTGTTACAAACAGGTG 
Perssons et al 2011 
Ra 5' - GCATTTCTCCATTCTCAGCAAAGTA Perssons et al 2011 
Rb 5' - GCATTTCTCCGTTTTCAGCAAAGTA Perssons et al 2011 
tcdC F 5' - FAM - 
AAAAGGGAGATTGTATTATGTTTTC 
Perssons et al 2011 
R 5' - CAATAACTTGAATAACCTTACCTTCA Perssons et al 2011 
cdtB F  5' -  FAM - 
TTGACCCAAAGTTGATGTCTGATTG 
Perssons et al 2011 
R  5' -  
CGGATCTCTTGCTTCAGTCTTTATAG 
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Table	  1.2	  C.	  difficile	  ribotyping	  Mastermix/Fragment	  analysis	  
Component Stock 
concentration 
ml of  
X100  
ml of  
X50 
Nuclease-free water - 251 125.5 
BSA 2 mg/ml 100 50 
Promega Flexi PCR Buffer X5 x5 200 100 
dNTP mix 2 mM 100 50 
MgCl2 25 mM 140 70 
Primer P3 (PET) 100 µM 2 1 
Primer P5 100 µM 2 1 
TAQ (Promega GoTaq) 5 U/µl 5 2.5 
Total volume (ml)  800 400 
Specimen added  200 100 
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Table	  1.3	  	  4-­‐plex	  toxin	  PCR	  mastermix	  
Component Stock concentration ml of  X100  
 
Nuclease-free water - 228.5 
Bovine serum albumin  2mg/ml 100 
PCR Buffer (Promega Flexi) X5 200 
NTP 2mM 100 
MgCl2 25mM 140 
Primer tcdA F (FAM) 100µM 8 
Primer tcdA R 100µM 8 
Primer tcdB F (FAM) 100µM 3.5 
Primer tcdB Ra 100µM 1.5 
Primer tcdB Rb 100µM 1.5 
Primer tcdC F (FAM) 100µM 1 
Primer tcdC R 100µM 1 
Primer cdtB F (FAM) 100µM 1 
Primer cdtB  R 100µM 1 
TAQ (Go Taq Promega) 5U/µl 5 
Total volume of mastermix  800 
Specimen to be added  200 
Reaction volume  1000 
 
HiDi formamide mix was prepared (8µl HiDi Liz 600 in 500 µl formamide buffer) 
and stored in aliquots of 1ml at -20ºC till needed. 
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2.7.4 PCR thermo cycling protocol 
The toxin multiplex and PCR ribotyping protocols were initially run on the same 
thermocycling protocol: 
• Initial denaturation at 95ºC for 5 min 
• 25 cycles of  95 ºC for 60 sec, 55 ºC for 60 sec and 72 ºC for 90 sec 
• Final extension at 72 ºC for 5 min.  
However since the initial reactions for ribotyping were rather weak, the cycle for 
ribotyping was later increased to 27 cycles. 
Products were stored at 4 ºC for a  maximum of 24h before post PCR dilutions. 
 
2.7.5 Post PCR dilutions 
After PCR, the products of the ribotyping and toxin gene multiplex were mixed as 
follows 
• First dilution: 18 µl nuclease free water 
                                   10 µl ribotyping PCR products 
 2 µl toxin gene PCR product 
This was mixed well by pipetting. 
• Final dilution, 1 µl of the diluted products were mixed with 9 µl of HiDi 
formamide mix.  
The final dilution was stored at -20 ºC till it could be sent to the sequencer for 
capillary gel electrophoresis. 
2.7.6 Gel electrophoresis 
Capillary gel electrophoresis was performed at the GenePool Sanger sequencing 
facility located at Ashworth Laboratories in the Kings Buildings, University of 
Edinburgh. Results were sent back from the sequencer in the form of FSA files, 
Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
37 
which were then analysed as follows to assign ribotypes by comparing with a set of 
known strains. 
2.7.7 Determination of ribotypes 
This was performed by GeneMarker®software version 1.95(Softgenetics, PA, USA). 
Known strains of ribotype 001, ribotype 106 and ribotype 027 were included with 
each run of ribotyping and toxin multiplex PCR for quality control. A panel of 
known FSA images for ribotypes 001, 002, 003, 005, 012, 014, 015, 017, 018, 019, 
020,023, 026, 027, 029, 046, 053, 056, 070, 075, 077, 078, 081, 087, 095, 103, 106, 
117, 126, 131, 174, 193, 216 and 258 was obtained from Dr Derek Fairley (Belfast).  
Another panel of strains with known ribotypes (confirmed by the anaerobe Reference 
Laboratory, Cardiff by agarose gel electrophoresis) was created for ribotypes 001, 
002, 009, 010, 011, 012, 013, 014, 015, 018, 020, 023, 026, 027, 029, 030, 032, 035, 
039, 042, 046, 050, 053, 054, 056, 057, 059, 064, 069, 070, 072, 081, 087, 092, 100, 
103, 104, 106, 111, 016, 119, 120, 125, 137, 142, 153, 154, 165, 170, 173, 176, 179, 
184, 186, 189, 192 and 210. Each unknown image was visually compared with the 
known panel to determine PCR ribotypes.  
The toxin gene images were compared against the PaLoc indicator panel (kindly 
provided by Dr Derek Fairley), which was loaded onto the software before analysis 
and automatically labelled the toxin gene products when they were loaded for 
analysis. 
Toxin gene fragments were analysed on the blue channel and ribotyping fragments in 
the red channel.  
 
2.8 PCR for Norovirus 
Dr Alison Hardie, clinical scientist at the Royal Infirmary of Edinburgh, performed 
the Norovirus PCR. The protocol for the PCR has been adapted from a previously 
published study (Kageyama et al., 2003).  
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2.8.1 DNA extraction 
Stool samples stored at -20°C were thawed and 10% (wt/vol) stool suspension was 
prepared with distilled sterile water and clarified by centrifugation at 3,000 × g for 20 
min. 200µL supernatant was extracted with the Biomerieux easyMag according to 
the manufacturer's instructions. RNAs were eluted with 100 µl of diethyl 
pyrocarbonate-treated water and kept at −80°C until used for PCR.  Known positive 
(Genogroup 1 or 2) and negative controls were included. 
 





Ring 1a HEX-AGATYGCGATCYCCTGTCCA-BHQ-1 
Ring 1b HEX-AGATCGCGGTCTCCTGTCCA-BHQ-1 
Ring 2 FAM-TGGGAGGGCGATCGCAATCT-BHQ-1 
 
2.8.3 Mastermix 
Mastermix was prepared using Express One-Step SuperScript qRT-PCR Kit 
(Invitrogen) . 
Per reaction:   
qPCR Supermix 10µL 
SuperScript Mix 2µL 
Primer/Probe mix* 2µL 
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*4µM each primer (COGs) and 0.8µM each probe (Rings) 
Final reaction volume 20 µL (14 µL mastermix +6 µL RNA. 
2.8.4 Thermocycing protocol 
50°C for 15 min,  
95°C for 20s  
45 cycles of 95°C for 3s, 60° for 30s (with fluorescence detection) 
2.9 Multilocus VNTR analysis (MLVA) 
MLVA was performed to subtype the isolates and look for strain relatedness. 
2.9.1 Isolates 
All isolates identified as ribotype 001, ribotype 002, ribotype 078 and multiple 
samples obtained from the same patient (if they were of the same ribotype). 
2.9.2 Protocols used 
Initially the 15 locus method described by Manzoor et al (2011) was attempted on all 
isolates including ribotypes 078. However after a few runs it became apparent that 
the protocol was inadequate to amplify all loci of ribotypes 078   In addition, some of 
the loci are likely to be different from the published sequence of the C. difficile strain 
630 on which the primers are based. Hence the protocol was modified to include only 
6 loci which were consistently amplifying in the 078 strains The PCR thermocycling 
conditions were modified to those published by Bakker et al (2010) and van den 
Berg et al (2007). 
2.9.3 DNA template preparation 
Same as section 1.7.2 
2.9.4 PCR primers   
Primers used for the loci amplified in the MLVA protocol are given in table 1.4 and 
the components of the mastermixes are given in table 1.5 
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Table	  	  1.4	  :Primers	  used	  for	  MLVA	  	  
Locus Primer sequence and fluorescent label Reference 
A6Cd F-FAM-TTAATTGAGGGAGAATGTTAAA van den Berg et al 2007 
 R-AAATACTTTTCCCACTTTCATAA van den Berg et al 2007 
B7Cd F-VIC-
CTTAATACTAAACTAACTCTAACCAGTAA 
van den Berg et al 2007 
 R-TTATATTTTATGGGCATGTTAAA van den Berg et al 2007 
C6Cd F-NED-GTTTAGAATCTACAGCATTATTTGA van den Berg et al 2007 
 R-ATTGGAATTGAATGTAACAAAA van den Berg et al 2007 
E7Cd F-VIC-TGGAGCTATGGAAATTGATAA van den Berg et al 2007 
 R-CAAATACATCTTGCATTAATTCTT van den Berg et al 2007 
G8Cd F-FAM-TGTATGAAGCAAGCTTTTTATT van den Berg et al 2007 
 R-AATCTAATAATCCAGTAATTTAAATT van den Berg et al 2007 
CDR60 F-NED-AGTTTGTAGGGAAGTGTGTAAATAGAT Marsh et al,2006 
 R-CGCATTAAATTTCACTCCTCAT Marsh et al,2006 
CDR5 F-PET-AGCCATTTTTATCAATCCTTTCTAT Marsh et al,2006 
 R-AATTTTAAGTTAACGTTTTTCTACAT Marsh et al,2006 
CD9 F-FAM-AAATAGAGAAATTGTTGTAGCACAAAG Manzoor et al, 2011 
 R-GTAAGGTGAGAAGCGGACT Manzoor et al, 2011 
CD12 F-VIC-TGACCCTTACAATAGCCAATCA Manzoor et al, 2011 
 R-ATCTGGCAGTTGATTCAGCA Manzoor et al, 2011 
CD14 F-NED-TTTCATAAAAGATTCCTTTCCTGT Manzoor et al, 2011 
 R-TGTGGTTGTTCCTGAAGTTTT Manzoor et al, 2011 
CD19 F-PET-AATTGGTAAGCAATCTGGACTTT Manzoor et al, 2011 
 R-TGCAGCTGGATATGTATCAGTTTA Manzoor et al, 2011 
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CD35 F-FAM-TTGGTGAAGCATTAATGGATGT Manzoor et al, 2011 
 R- CGGCAATGCTTTGAACTATG Manzoor et al, 2011 
CD44 F-PET-TGCTGCGATAAGCTCTGCTA Manzoor et al, 2011 
 R-TCATTTCCATTCAAATTATGTGACTAT Manzoor et al, 2011 
CD102 F-NED-GCGTACAAGAGGTCGGAGTC Manzoor et al, 2011 
 R-CCACCCTCACTTTATTCAAACC Manzoor et al, 2011 
CD105 F-PET-TCAGCAACAGCAGAGGAAAG Manzoor et al, 2011 
 R-CATTTGTCTCATACTCGGTTCAA Manzoor et al, 2011 
 
2.9.5 Mastermixes for MLVA 
Table	  1.5	  MLVA	  PCR	  mastermix	  
Component Stock 
concentration 
ml of  
X1 
ml of  X30 
Nuclease-free water - 16.3 µl 489µl 
PCR Buffer (GeneAmp PCR 
Gold buffer) 
1X 2.5 µl 75µl 
dNTP 10 mM 0.5 µl 15µl 
MgCl2 25mM 2.5 µl 75µl  
Primer  F 100 µM 0.05 µl 1.5µl 
Primer  R 100 µM 0.05 µl 1.5µl  
TAQ (AmpliTaq Gold DNA 
polymerase (Applied 
Biosystems)  
5U/µl 0.1 µl 3µl 
Total volume of mastermix  22 µl 800 
Specimen o be added  3 µl 90 
Reaction volume  25 µl 1000 
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For the loci B7Cd, G8Cd and C6Cd of ribotypes 078 only, the amount of magnesium 
used was increased to 4mM . 
2.9.6 Thermocycling protocol for MLVA 
MLVA loci (for all isolates except ribotypes 078) were amplified using the protocol 
of Manzoor et al (Manzoor et al., 2011). 
• Initial denaturation at 95ºC for 5 min 
• 35 cycles of  95 ºC for 60 sec, 56 ºC for 60 sec and 72 ºC for 60 sec 
• Final extension at 72 ºC for 5 min. 
 
2.9.7 Modifications for ribotype 078 
Since ribotypes 078 loci were not consistently amplifying at the protocol of 
(Manzoor et al., 2011)  the protocol was modified to that used by Bakker et al. 
(Bakker et al., 2010). 
• Initial denaturation at 95ºC for 15 min 
• 35 cycles of denaturation at 94 ºC for 30 sec, annealing at 51ºC (47 ºC for 
B7Cd and G8Cd and 46ºC for C6Cd) for 30 sec and elongation at 72 ºC for 
30 sec. 
• Final extension at 72 ºC for 10 min. 
2.9.8 Post PCR dilutions 
After PCR, the products of loci were mixed to form four panels each composed of 
four (or three) loci, designed to contain one each of the four different fluorescent 





Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
43 
Table	  6	  Details	  of	  the	  loci	  amplified	  in	  the	  MLVA	  scheme	  
Locus Panel/label Size of 
repeated 
sequence 
No of alleles 
in strain 630 
A6Cd A/BLUE 6 34 
B7Cd A/GREEN 7 16 
C6Cd A/YELLOW 6 15 
CDR5 A/RED 8 11 
CDR60 B/YELLOW 17 15 
E7Cd B/GREEN 7 7 
G8Cd B/BLUE 8 6 
CD44 C/RED 42 6 
CD9 C/BLUE 42 11 
CD12 C/GREEN 42  2 
CD14 C/YELLOW 45 6 
CD19 B/RED 76 3 
CD35 D/BLUE 41 9 
CD102 D/YELLOW 50 6 
CD105 D/RED 45 4 
• First dilution 1 µl of each PCR product according to the panel given in table 6 
into 6µl nuclease free water. This was mixed well by pipetting.  
• Second dilution was performed by adding 1µl of first dilution products (4 loci 
in each well) to 6µl nuclease free water (1:10 dilution). 
• The final dilution, 1µl of the diluted products were mixed with 9µl of HiDi 
formamide mix. 
The final dilution was stored at -20 ºC till it could be sent to the sequencer for 
capillary gel electrophoresis. 
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2.9.9 Modifications to post PCR dilutions 
It was observed that using the four panels there were experiments where all the loci 
did not show products. If that happened the loci were run individually to avoid 
inhibition of the fluorescent signals by other stronger signals. When this was done 
the dilution was altered to be 
• First dilution 25µl of each PCR product into 125µl nuclease free water (1:5 
dilutions). This was mixed well by pipetting.  
• The second dilution was performed by adding 1µl of the first dilution 
products to 9µl of nuclease free water. 
• The final dilution, 1µl of the diluted products were mixed with 9µl of HiDi 
formamide mix. 
The final dilution was stored at -20 ºC till it could be sent to the sequencer for 
capillary gel electrophoresis. 
2.9.10 Analysis of MLVA  
This was performed by GeneMarker®software version 1.95(Softgenetics, PA, USA). 
Control strain 630 was included in each run. The product size for each locus was 
determined and the number of alleles calculated by subtracting the flanking regions 
and dividing the number of remaining base pairs with the number of base pairs in the 
repeat motif . This information was kindly provided by Susan Manzoor (Manzoor et 
al., 2011). 
2.9.11 Cluster analysis 
This was performed using Bionumerics version 2.5(Applied Maths BVBA, Texas 
USA). Clustering was performed according to MLVA type to determine genetic 
relationships. The summed absolute distance was used as the coefficient for 
calculating the minimum spanning tree. 
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2.10 Clinical case definitions 
These were adapted from SHEA and HPA guidelines (HPA, 2008, McDonald et al., 
2007) 
2.10.1 Case 
For the purpose of inclusion into the study, a case was defined as a patient with   
diarrhoea where the stool takes the shape of the container (grade 5-7 as per Bristol 
stool chart) or toxic megacolon with stool positive for C. difficile  toxin A and /or B 
without other known aetiology  (McDonald et al., 2007).  
2.10.2 Episode 
An episode of CDI was defined as a case with the criteria above who remains 
continuously symptomatic with a break of less than 48h in symptoms attributable to 
CDI.  
2.10.3 Repeat episode/recurrence 
When following up the patients, a repeat episode was defined as diarrhoea without 
another demonstrated cause where the stool was positive for C. difficile  by toxin 
EIA+GDH, toxic megacolon, pseudomembranous colitis demonstrated on 
colonoscopy, or symptoms recurring where the physician recorded it as another 
episode of CDI with at least 48h of an intervening asymptomatic period  after 
completion of initial treatment. This definition was different from the initial case 
definition because the diagnostic lab does not test patients for C. difficile toxin within 
28 days of a previous toxin positive stool as per Department of Health guidelines 
(HPA 2008).  
2.10.4 Hospital-associated infection 
This was defined as CDI, which developed after 48h of admission into a health care 
facility (HCF), see chapter 5 figure 5.1.  
2.10.5 Community-associated infection 
This was defined as CDI, which developed in a patient with no history of health care 
contact within 12 weeks of admission or within 48h or admission into a hospital 
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without previous health-care contact in the past 12 weeks.  However for the purpose 
of some analyses this definition was altered to include patients who were  
a. Admitted in nursing homes (without admission to a hospital in the past 12 weeks). 
These facilities are more similar to old age homes and do not have a doctor present in 
the premises 
 b. Had contact with a hospital in the past 4-12 weeks (indeterminate category by 
SHEA definitions). 
Patients admitted to hospital similar to long-term care facilities were excluded from 
CA-CDI and were included in HA-CDI instead.  
This definition varies slightly from the European definition European which include 
patients who have not had contact with health care in the past 30d as CA-CDI 
(Kuijper et al., 2007). 
2.10.6 Health care associated infection 
This was defined as CDI developing in a patient within four weeks of contact with a 
health care facility (including GPs and outpatient contact) but less than 48h after 
admission to a HCF. For the purpose of some analyses, this was included in the 
hospital–associated category (see figure 5.1).  
2.10.7 Severe infection  
The definition of severity varies from study to study. Various studies have used 
differing end points when evaluating patients for severe disease. Although the HPA 
guidelines (HPA, 2008) suggest calling a case as severe or life threatening if S 
associated with a WCC >15 X109/L, or an acute rising serum creatinine (i.e. >50% 
increase above baseline), or a temperature of >38.5°C, or evidence of severe colitis 
(abdominal or radiological signs), hypotension, partial or complete ileus or toxic 
megacolon, or CT evidence of severe disease , other studies have used 
hypoalbunemia  and admission into intensive care or surgical intervention due to 
CDI related complications in the definition (Hensgens et al., 2011).  
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At the Royal Infirmary of Edinburgh a composite definition of severity is used to 
define severe infection for the purpose of treatment. All non-severe cases get 
metronidazole as the first line treatment whereas all severe; life threatening and 
complicated cases get Vancomycin as first line treatment. For the purpose of 
consistency with clinical practice, the definition of severity adopted in this study was 
the same as the definition used at the Royal Infirmary of Edinburgh.  Hence, a severe 
case of CDI was defined as a case where the patient developed any of the following 
markers of severity anytime between the onset and cessation of the symptoms in an 
episode of CDI. 
• History of admission to an intensive care unit for complications associated 
with CDI 
• History of surgery (eg, colectomy) for toxic megacolon, perforation, or 
refractory colitis attributed to CDI 
• Total leucocyte count ≥15 cellsX109/L 
• Acute rising serum creatinine (i.e. >50% increase above baseline) 
• Temperature of >38.5°C 
• Evidence of severe colitis (pseudomembranous colitis, abdominal or 
radiological signs) 
• Raised lactate  
• Albumin ≤ 25g/L 
2.10.8 Cause of death 
Mortality data was obtained from the NHS Lothian Public Health Department. Cause 
of death was determined by reviewing the ICD codes on the death certificates. 
ICD10 codes A04.7, A09, A41.4, A49.8 (on either primary or secondary 
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2.10.9 Immunosuppression 
This was defined as the presence of   one or more of the following conditions 
• Acquired Immunodeficiency Syndrome (AIDS) 
• Organ transplant (solid organ or haematopoietic stem cell transplant) 
• Neutropenia 
• Immunosuppressive drug use or systemic corticosteroids for >1 month. f   
• Corticosteroid use >10 mg. 
•  Chemotherapy in last two months 
 
2.11 Statistical analysis 
This was performed using Minitab® statistical software version 15.1.0.0 
Fisher’s exact text and chi square were used to for categorical variables and two-
sample t test for numerical variables. Multivariate analyses were performed using 
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3.1 Source of samples 
Four hundred and twelve samples from 345 patients (corresponding to 432 clinical 
episodes) which were positive with GDH and Toxin ELISA combination testing.  Of 
these 10 samples were from patients under two years of age. Since the significance of 
toxin positivity from this age group is not clear, these were removed from further 
analysis. Hence 402 samples corresponding to 432 clinical episodes were analysed. 
The clinical area these samples came from is given in figure 3.1. As expected, the 
majority of samples were obtained from geriatrics, which would be in keeping with 
the median age of 73 years (see figure 3.2).  This reflects the trend in previous years 
(Reddy et al., 2010). Interestingly, the next common source was general practice, 
which contributed to 17.3% of all episodes.  However, of 74 requests from GPs, only 
23 (31.1%) did not have a previous contact with a health care setting in the preceding 
12 weeks and hence were not community associated in the strictest sense.  
In addition, acute services, including the accident and emergency department and the 
immediate care departments accounted for 29 (6.7%) requests, which included HA-
CDI (recently discharged), as well as CA-CDI cases with an acute presentation.  
As expected, the specialties of infectious diseases and general surgery (where 
complex CDI cases are managed) accounted for a large proportion as well (10.7% 
together). 
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Figure	  3.1	  Distribution	  of	  clinical	  specialty	  from	  where	  samples	  were	  obtained.	  Twenty-­‐six	  	  
episodes	  were	  repeat	  episodes,	  which	  were	  clinically	  diagnosed	  without	  testing	  a	  stool	  samples,	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3.2 Patient demographics 
3.2.1 Age and distribution 
The age distribution of the patients ranged from 2 years to 97 years. Of the 335 
patients 2.6% were under 18 years, 24.2 % from 18-60 years and the remainder 
73.1% were over 60 years of age.  A graphical and statistical summary is given in 
figure 3.2. The gender distribution of the entire population is given in figure 3.3 and 
the age stratified gender distribution is given in figure 3.4. Of note, the female 
prevalence in the overall population was 63.9%. No statistically significant 
difference in gender was found overall. However, the gender distribution after 80 
years age was statistically significant when compared to the prevalence in <80 year 
olds (p =0.0213). 
Figure	  3.2	  Graphical	  presentation	  and	  statistical	  summary	  of	  the	  age	  distribution	  of	  the	  patient	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Figure	  3.3	  Gender	  distribution	  of	  the	  patient	  population	  included	  in	  the	  study.	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3.2.2 Proportion of patients with severe CDI 
Severe and non-severe episodes were identified based on criteria set forth in Chapter 
2. Patients from general practice who were not tested for severity markers and did 
not get admitted into hospital subsequently were included in the non-severe group. 
Patients who were from non-community sources but were not tested for severity 
markers are included in the indeterminate group (see figure 3.5: data not available). 
Further analysis of severe and non-severe episodes is in chapter 4. 
Markers of severity for the entire study population (total leucocyte count and serum 
albumin levels) are given in figure 3.6 and 3.7. Further details of these are discussed 
in the subsequent chapters. 
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Figure	  3.6	  Graphical	  presentation	  and	  statistical	  summary	  of	  the	  total	  leucocyte	  count	  
(cellsX109/L)	  results	  of	  episodes	  from	  the	  study. 
 
Figure	  3.7	  Graphical	  presentation	  and	  statistical	  summary	  of	  the	  serum	  albumin	  level	  (g/L)	  from	  
patients	  taken	  from	  each	  episode.	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3.2.3 Proportion of patients with repeat episodes of CDI 
Figure 3.8 shows the summary of patients stratified according to the number of 
episodes on record. These include all the episodes on medical records including those 
prior to commencement of this study. Most patients (70.7%) suffered a single 
episode while the remainder (29.3%) had multiple episodes ranging from 2-10 
episodes. Similar data limited to the duration of the present study is given in figure 
3.9, where 19.9% patients suffered from relapsing or recurrent disease (classified as 
repeat episodes for the purpose of this study). These data corresponds well with a 
previous American study, which reported a 29% relapse rate over a 15-month period 
(Cadena et al., 2010) and from a recent study from Oxford which reported a 
cumulative recurrence rate of 22% (Eyre et al., 2012). Further analysis of recurrent 
cases is given in chapter six. 
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Figure	  3.9	  Summary	  of	  episodes	  per	  patient	  occurring	  in	  the	  duration	  of	  the	  present	  study	  (12-­‐
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3.2.4 Place of acquisition of CDI 
The place of acquisition of the first episode in the study from each patient was 
defined as given in chapter two.  Since all previous available data were taken into 
account, if a patient had a previous episode in the past 12 weeks (even though it was 
not part of the study), such a patient was considered to have acquired it from a 
health-care setting. More details of community and health-care associated CDI are 
given in chapter five.  



















Slice labels: N, %
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3.2.5 Charlson Comorbidity index 
Charlson comorbidity index (CCI) was available for 333 patients. Although the 
unadjusted version was also recorded, the age-adjusted version was used in the 
analyses. Graphical and statistical summary of the distribution of the CCI of the 
patients in the study is given in figure 3.11. In this study 19.2% patients had a 
Charlson score of 0. More details among the subgroups of patients with CDI are 
given in the relevant chapters.  
 
Figure	  3.11	  Graphical	  presentation	  and	  statistical	  summary	  of	  the	  age-­‐adjusted	  Charlson	  score	  of	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Summary for Charlson co-morbidity index (age adjusted)
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3.3 Predisposing factors 
Predisposing factors analysed in the study are depicted graphically in figure 3.12 to 
figure 3.17 
3.3.1 Antibiotics 
Antibiotic information was retrospectively recorded for the eight weeks preceding 
CDI diagnosis. The different antibiotics recorded for the patients along with the 
proportion who received each are given in figure 3.13. The number of different 
antibiotics given per patient according to this classification is given in figure 3.12. 
A very well-known predisposing factor for development of CDI, the various classes 
of antibiotics likely to predispose to CDI have been studied in many previous 
studies(Gorbach, 1999). The recent focus on reduction in the use of “high risk” 
antibiotics to reduce the overall incidence of CDI has also been studied (Aldeyab et 
al., 2012, Valiquette et al., 2007). Further analysis of antibiotics as a risk factor is 
presented in the following chapters. 
Figure	  3.12	  Graphical	  and	  statistical	  summary	  of	  antibiotics	  administered	  per	  patient	  in	  the	  eight	  
weeks	  preceding	  CDI	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Figure	  3.13	  Antibiotics	  given	  to	  patients	  in	  eight	  weeks	  preceding	  CDI	  
amoxicillin/clavulanic acid Piperacillin/tazobactam Quinolones 3rd generation cephalosporins
2nd generation cephalosporins Tetracyclines Glycopeptides Macrolides
Gentamicin Flucloxacillin Meropenen Penicillin V
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N=303 patients
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3.3.2 Acid suppressive agents   
The use of acid suppressing medication was found in 51.3% patients.  Studies have 
suggested that the use of antacids can be a predisposing factor for C. difficile 
colonisation (McFarland et al., 1990). The proportion of patients on acid suppression 
medication up to two weeks before development of CDI is given in figure 3.14. 
Figure	  3.14	  Proportion	  of	  patients	  on	  acid	  suppressive	  at	  the	  time	  of	  developing	  CDI	  
 
 
Of the 172 patients that were given antacids, Omeprazole was administered to 105 
patients (61%), Lanzoprazole to 43 patients (25%), Ranitidine to 24 patients (14%, 
Pantoprazole to 5 patients (2.9%) and Esomeprazole to 3 patients (1.7%). Of the 
above, eight patients were given more than one antacid (2 Lanzoprazole and 
Omeprazole, 5 Omeprazole and Ranitidine, 1 Ranitidine and Lansoprazole) in the 
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3.3.3 Underlying gastrointestinal pathology   
In this study, gastrointestinal pathology was found in 45.5% patients. The 
distribution of the various types of GI pathology seen in the study population is given 
in figure 3.15. Inflammatory bowel disease was seen in 6.6.% of the population 
 












Malignancy of GI tract
Structural abnormality
Other inflammatory conditions







Details of underlying gastrointestinal pathology
N=335
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Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
63 
3.3.4 Gastrointestinal invasive procedure 
A total of 19.1 % patients underwent a gastro-intestinal invasive procedure in the 12 
weeks preceding development of CDI. The distribution is depicted in figure 3.16 
 
Figure	  3.16	  Proportion	  of	  patients	  who	  underwent	  an	  invasive	  gastrointestinal	  procedure	  in	  12	  






Invasive gastrointestinal procedure in 12 weeks preceding CDI
N=335
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Fifty-seven patients in the study were deemed to be immunosuppressed as defined in 
section 1.10.8. This corresponds to 17% of the total population as seen in figure 3.17 


















Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
65 
3.3.6 Mortality 
One-year mortality among patients with CDI including cause of death is given in 
figure 3.18. Time to death is given in figure 3.19 and cause of death in the 30d time 
range is given in figure 3.20. It is apparent that death due to CDI may occur even 
after 30d of developing CDI (13 patients in the present study). Conversely death 
within 30d of CDI may not be due to CDI (69.8% in the present study).  
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Figure	  3.19	  Mortality	  and	  time	  to	  death	  among	  patients	  included	  in	  the	  study	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3.3.7 Treatment given for CDI  
The antibiotic combinations given to patients in the study are given in figure 3.21. 
Two patients received rifamycin in addition to vancomyin and metronidazole. No 
patient was given faecal transplant therapy though it was considered as an option for 
two patients with recurrent CDI. One patient was given IV immunoglobulin in 
addition to vancomycin and rifamycin. Treatment given has been further analysed in 
the following chapters. 
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3.3.8 Co-infection with other GI pathogens 
All stool samples sent to the enteric laboratory at the Royal Infirmary of Edinburgh 
are tested for the presence of C. difficile (if requested) and cultured for other bacterial 
pathogens (with special media added as per the travel history).  Norovirus PCR is 
done if an outbreak is suspected. In the present study, additional Norovirus tests were 
done on stool samples thought to be representing CA-CDI. The proportion of patients 
in whom other diarrhoeal pathogens were found is given in figure 3.22. Of the six 
patients with co-infections (three Campylobacter and three Salmonella spp), five 
were treated with metronidazole by the attending clinician, in spite of the presence of 
another pathogen. Similarly 12 of the 14 episodes (85.7%) with Norovirus co-
infection were treated for the C. difficile (eight received metronidazole, one 
metronidazole with vancomycin and three vancomycin alone).  These samples have 
not been excluded from the study since it could not be determined whether their 
symptoms were solely due to the other pathogen or due to a co-infection. 








Co-infections with other GI pathogens
N=428 episodes of infection
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3.3.9 Co-infection with MRSA and VRE 
Methicillin resistant Staphylococcus aureus (MRSA) and Vancomcin resistant 
Enterococci (VRE) are largely hospital-acquired organisms (HAI) (though 
community acquired strains exist, the proportion is relatively small). At the time of 
inclusion into this study, the previous acquisition of either of these pathogens was 
determined and during the one-year follow up period the acquisition of either of 
these pathogens was also recorded.  Among the 335 patients included in this study, 
25.1% were also colonised with either VRE or MRSA.  56.4% of these had pre-
existing colonisation before they developed the first episode of CDI whereas in 
43.6% colonisation was detected simultaneously or within a year of developing CDI.  
Although not part of the original planned study, this additional data suggests that at 
least 25% of patients with CDI are at greater risk of developing multiple HAI-s (see 
figure 3.).The C. difficile maybe a consequence of antimicrobial treatment for 
MRSA/VRE, which is likely to increases the susceptibility to CDI (which would 
explain the later acquisition of C. difficile). Conversely it could be a result of 










Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
70 
Figure	  3.23	  Co-­‐infection	  with	  MRSA	  and/or	  VRE	  prior	  to	  or	  within	  1	  year	  of	  developing	  CDI	  
 
3.4 Molecular epidemiology 
3.4.1 Prevalence of PCR ribotypes 
Results of PCR ribotyping are given in figure 3.24. Samples from 54 episodes 
(19.2%) were unavailable for typing since they were repeat episodes which were 
either diagnosed solely on the basis of clinical criteria or the sample sent was 
insufficient in quantity for culture (but sufficient for toxin and GDH tests), or the 
culture did not yield C. difficile. At least one sample was available from 94.6% 
patients. Hence isolates from 94.6% patients and 80.8% episodes were available for 
typing.  Of these, isolates from 28 episodes were typed but a ribotype number could 
not be assigned since the image did not exactly resemble any in the reference 
collection. These isolates were compared with each other and save two isolates from 
the same patient; all others possessed patterns different from each other.   
PCR ribotype 001 was the commonest in the entire population followed by ribotype 
002, 005 and 014. It was not possible to reliably distinguish between ribotypes 014 
and 020 in the case of four isolates, and hence they have been clubbed together in the 










Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
71 
these two ribotypes since they cluster very closely in the minimum spanning tree 
even when typed using the 15 locus MLVA (Manzoor et al., 2011). On agarose gel, 
these two ribotypes are very similar (differing only in the intensity of a single band). 
Although capillary gel electrophoresis is known to be more accurate than agarose gel 
(Indra et al., 2008, Xiao et al., 2012), the patterns for these two ribotypes are difficult 
to distinguish in some cases. Indra et al (2008), found 7 different patterns for 
ribotype 014 when comparing agarose and capillary gels with MLVA. Hence there 
appears to be diversity within this group, which is reflected in the present study. 
Figure 3.25 shows the capillary gel electrophoresis images of known ribotype 014 
and 020.  
In Scotland, the Scottish Salmonella, Shigella and C. difficile reference lab 
(SSSCDRL) reported a change in the most prevalent ribotypes from July 2010-June 
2011. This data is from the snapshot study conducted by the SSSCDRL, which 
includes approximately 15% of all isolates from each region of Scotland. There was 
a changing trend among the commonest ribotypes from ribotype 015 (11%), 001, 002 
and 106 (all at 10%), 014 (8%), 027 (8%), 078 (7%), 020 (6%) in the third quarter of 
2010 (HPS, 2011d) to  ribotype 106 (12%), 015 (10%), 001 (10%), 005 (8%), 002 
(8%), 078 (8%), 020 (8%), 014 (7%) and 027 (4%) in the last quarter of 2010 (HPS, 
2011e). Further changes were noted in early 2011: ribotype 106 was the most 
common strain (15% of isolates typed) followed by types 002 and 020 (both at 12%) 
and type 001 (6%). Ribotype 027 was absent from this quarter. (HPS, 2011c). The 
changing trend continued with a decline in types 106, 001 and 027 whereas types 
005, 023 and 078 emerged in greater numbers (HPS, 2011b). In spite of this 
changing trend, the 10 most common ribotypes in these reports are also the 
commonest ribotypes in the present study, hence reflecting the overall prevalence in 
Scotland. Interestingly, though ribotype 027 has been reported in Scotland in areas 
very close to Edinburgh (above data), only one case of this ribotype has ever been 
reported within Edinburgh itself.  In keeping with this trend, the present study also 
did not find any of this so called “hypervirulent” strain.   A recent study 
demonstrated that due to slight differences in banding patterns, ribotypes 176, 198 
and 244 resemble PCR ribotype 027 (Valiente et al., 2012). Although PCR 176 was 
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present in the library, we did not find any isolate resembling it. The latter two 
patterns were absent from the library, hence there is a small chance that they may be 
identified in the strains currently called untypeable. 










































































































Molecular typing of episodes:PCR Ribotyping
N=428
NA= 54 episodes were either only clinically dignosed or sample insufficient for culture
NT=28 isolates were not typeable since they did not exist in the database
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3.4.2 Presence of toxin A, toxin B, the binary toxin and deletions in the 
negative toxin regulator tcdC 
All isolates in the study were tested for the presence of toxin A and toxin B genes 
tcdA and tcdB. These were found to be present in all strains. In addition, the binding 
component of the binary toxin cdtB and known deletions in the anti-sigma factor 
tcdC was also investigated. The latter was found in 11.1% episodes. The results of 
these are given in table 3.1. 
Table	  3.1	  Deletions	  in	  tcdC	  found	  in	  the	  study.	  
Deletion Number found Percent of total 
episodes 
Found in study 
ribotypes 
53bp 13 3.1 023 
19bp 14 3.47 015 
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Factors associated with severe infections 
 
In this chapter comparisons have been made between three groups as follows: 
• Severe and non-severe episodes where each episode has been taken as an 
individual unit. Patients with multiple, distinctly separate episodes have been 
included more than once. This was to analyse separately the episodes from 
which a patient has recovered and completed treatment. These episodes are 
sometimes due to a separate ribotype as seen in chapter 6. 
• Patients who developed an episode of severe CDI at presentation or within 
one year of the presenting episode with those whose episodes were never 
classified as severe. 
• Patients who died within one year of the presenting (index) episode and CDI 
was listed as a cause of death on the death certificate with those who did not 
die or died to non CDI related causes. 
4  
4.1 Molecular aetiology   
4.1.1 Ribotypes associated with severe and non-severe episodes 
Severe episodes in this study were compared to non-severe episodes. Figure 4.1 
depicts the ribotype distribution between these two groups. Among the severe 
episodes, ribotype 001 was present in the maximum proportion (15.8%) and ribotype 
002 was the second commonest (11.4%). Ribotypes 005 and 078 accounted for 9.5 
and 9.4% each. Figure 4.2 gives the relative proportion of ribotypes among the 
severe episodes. As is apparent from these two graphs, there is heterogeneity within 
this population and no particular ribotype is over-represented in the severe episodes 
as compared to the non-severe episodes. Comparing the severe and non-severe 
episodes of the commonest ribotype 001, there was no significant difference 
Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
76 
(p=0.667). Comparisons of other common ribotypes did not yield any statistically 
significant differences either. Although it may appear that representing each episode 
is likely to over-represent the prevalence of CDI due to a particular ribotype, it does 
correlate the workload of the hospital staff and the morbidity faced by the patient. 
The 28-day rule to call an episode separate from the previous has not been followed 
strictly to enable a uniform strategy to analyse the molecular aetiology.     
As discussed earlier, there have been suggestions that the ribotype of a C. difficile 
isolate may determine its potential to cause severe disease (Arvand et al., 2009, 
Baldan et al., 2010). There have been reports of PCR-ribotype related differences in 
susceptibility to antimicrobials and disinfectants (Dawson et al., 2011, Huang et al., 
2009a), which may be responsible for differences in pathogenicity. However a 
number of multivariate analyses now appear to be suggesting that severity is not 
related to ribotype whereas there is a positive correlation with haematological 
markers of severity like total leucocyte count and serum albumin (Walk et al., 2012, 
Wilson et al., 2010).  
Ribotyping does however, provide a method for classifying C. difficile isolates, 
which is often required for epidemiological purposes and is a good starting point for 
comparative studies. 
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4.1.2 Differences in toxin genes tcdC and cdtB  
The presence of the binary toxin and deletions in the toxin suppressor gene (anti-
sigma factor) was studied. The results were compared between the groups mentioned 
above (see table 4.2, 4.5, 4.8 and 4.9). Neither of these was statistically different 
between the severe and non-severe episodes (p values 0.418 and 0.779 respectively), 
nor between patients who developed a severe episode at presentation (or within one 
year of the presenting episode), see table 4.5. However when the patients who died 
due to CDI (with CDI listed on the death certificate) within one year of the 
presenting (index) episode were compared with those did not die due to CDI (either 
alive at one year, or dead due to other causes), a significant difference was found 
between the presence of a deleted tcdC (p=0.013, see table 4.8) and presence of the 
binary toxin (p=0.014). However this difference was not found in the regression 
model (table 4.9) and the confidence interval was very large suggesting that the 
numbers included in the analysis (28 patients who died) was probably too low to 
make a strong conclusion.    
Since ribotype 027 and ribotype 078 have been identified with the binary toxin and 
deletions in the tcdC (strains which have frequently been associated with outbreaks 
and reported increase in mortality), there was a suspicion that their deletion in the 
tcdC or presence of binary toxin may have influence of their virulence. An overall 
genetic relationship between strains which harbour mutations in the toxin regulatory 
genes has been suggested (Bouvet and Popoff, 2008) raising the question that 
increased virulence may be a feature associated with these mutations (Carter et al., 
2011, Knetsch et al., 2011). However doubts had been raised earlier regarding the 
significance of gene deletions in gene functionality (Curry et al., 2007) and clinical 
studies performed so far have also not confirmed this suspicion. Analysis of 207 
clinical isolates with and without the presence of tcdC truncation and binary toxin   
for severity markers and outcome revealed that there was no direct correlation 
between these parameters and disease outcome (Goldenberg and French, 2011). 
However the study suggested that the presence of binary toxin may be associated 
with increased total leucocyte count and all cause mortality at 30 days. Another study 
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compared 141 patients of whom 42 of had deletion-positive C. difficile. They 
concluded that the deletion-carrying C. difficile was commonly present but did not 
cause more severe disease (Verdoorn et al., 2010).  
Another study compared the 30-day mortality rates for patients infected with 
Clostridium difficile strains with and without binary. Patients with binary toxin had 
higher case-fatality rates than patients without binary toxin, in univariate   and 
multivariate analysis after adjustment for age, sex, and geographic region (RR 1.6, 
95% CI 1.0-2.4) (Bacci et al., 2011) 
From these studies and from the present study it appears that any correlation between 
gene mutation and clinical severity if present is unlikely to be due to the deletions 
detected in these studies. However there may be a factor indirectly related to these 
mutations, which may still not be known. The presence of binary toxin appears to be 
linked to severity but the reason is unclear. Further molecular work with clinical 
correlation is needed before such an association can be established confidently. 
Advances in molecular technology are already leading to more detailed work on this 
subject. Point mutation in the tcdC leading to a truncation in the protein of PCR 
ribotype 027 have suggested that this mutation is more likely to be associated with 
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4.2 Clinical parameters 
The factors compared between the severe and non-severe episodes are given in table 
4.1 and 4.2. Table 4.3 summarises the multivariate analysis of the factors, which 
were found to be significantly different, by the bivariate analysis. 
Table	  4.1	  Bivariate	  analysis	  of	  continuous	  clinical	  variables	  comparing	  all	  severe	  episodes	  with	  
all	  non-­‐severe	  episodes	  
Variable Severe episodes Non-severe episodes p 
value 
p value  
N 
 
















174   5.46    2.65      0.20 206   4.44    3.43      0.24 0.001 0.0054 





158     
 
2.13 1.41      0.11 187   
 
1.76    1.33     0.097 0.015   0.0098 
Total number of 
episodes on 
record 




169      16.96 9.42      0.72 158    9.49    3.60      0.29 0.000 0.000 
Serum albumin 
level at onset 
(g/L) 
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Table	  4.2	  Bivariate	  analysis	  of	  categorical	  variables	  comparing	  all	  severe	  and	  non-­‐severe	  
episodes  






Total N p value 
(Fisher’s 
exact test ) 
Gender Male  61 74 135  1.0 
Female 113 137 250 
Immunosuppression Absent 131 186 317   
 0.000 Present 43 23 66 
Place of acquisition CA 26 56 82  0.007 
  HA 117 122 239 
Antacids (PPI and H2 
receptor antagonists) 
Given 94 96 190 0.099 
Not given 60 89 149 
Underlying GI pathology Not known to 
be present 
76 130 206 0.000 
Present 98 80 178 
Mutation detected in 
tcdC 
Absent 5 8 13 0.779 
Present 131 162 293 
Colonisation with MRSA 
or VRE prior to CDI   
No 135 165 300 0.901 
Yes 39 45 84 
Invasive GI procedure in 
12 weeks prior to CDI 
No 118 167 285 0.003 
Yes 55 37 92 
Use of tazocin in eight 
weeks preceding illness 
 No 86 142 228 0.000 
 Yes 75 48 123 
Use of clindamycin in 
eight weeks preceding 
CDI 
No 160 182 342 0.042 
Yes 1 8 9 
Antibiotics given 8 
weeks prior to CDI 
No 12 21 33 0.28 
Yes 151 174 325 
Presence of cdtB No 136 170 306 0.418 
Yes 22 21 43 
Norovirus co-infection No 50 96 146 0.390 
Yes 3 11 14 
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Table	  4.3:	  Multivariate	  analysis	  by	  binary	  logistic	  regression	  of	  factors	  significantly	  associated	  
on	  bivariate	  analysis	  for	  development	  of	  a	  severe	  episode	  compared	  to	  non-­‐severe	  episodes	  
Variable p value Odds Ratio 95% CI 




0.005    
 
1.13    1.04 1.23 
Immunosuppression  0.005    
 
1.13    1.04 7.75 
Presence of 
underlying  GI 
pathology 
0.063    1.65    0.97 2.80 
Hospital-associated 
acquisition 
0.632    1.17    0.61 2.25 
Invasive GI 
procedure in 12 
weeks preceding 
episode 
0.086    1.72    0.93 3.19 
Piperacillin-
tazobactam 8 weeks 
prior to episode 
0.016    1.98    1.13 3.46 
Clindamycin 8 
weeks prior to 
episode 
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Table	  4.4	  Bivariate	  analysis	  of	  continuous	  variables	  analysed	  for	  differences	  between	  patients	  
who	  developed	  a	  severe	  episode	  at	  presentation	  or	  within	  the	  one-­‐year	  follow	  up	  period	  to	  
those	  who	  did	  not	  develop	  any	  severe	  episode	  
Variable Development of any severe 
episode 








Mean SD SE  
Mean 
Age (years) 153   
 





153   
 
5.38    2.75      0.22 168   4.28    3.47      0.27 0.002 
Total number of 
different 
antibiotics given 
eight weeks  
preceding  onset 
138   2.07    1.33      0.11 153   1.71    1.28      0.10 0.018 
Total number of 
episodes on 
record 




149   16.67    9.35      0.77 129    9.43    3.83      0.34 0.000 
Serum albumin 
level at onset 
(g/L) 
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Table	  4.5	  Bivariate	  analysis	  of	  categorical	  variables	  analysed	  for	  differences	  between	  patients	  
who	  developed	  a	  severe	  episode	  at	  presentation	  or	  within	  the	  one-­‐year	  follow	  up	  period	  to	  
those	  who	  did	  not	  develop	  any	  severe	  episode	  
Variable  Development of 
any severe 
episode   N  
No severe  





exact test ) 
Gender Male 55 61 116 1.0 
Female 98 109 207 
Immunosuppression Absent 116 153 269 0.001 
Present 37 17 54 
Place of acquisition CA 30 52 82 0.029 
HA 123 118 241 
Antacids (PPI and H2 
receptor antagonists) 
Given 84 82 166 0.078 
Not given 51 76 127 
Underlying GI 
pathology 
Not known to 
be present 
70 107 177 0.002 
Present 83 63 146 
Deletion detected in 
tcdC 
Absent 115 134 249 0.353 
Present 27 23 50 
Colonisation with 
MRSA or VRE prior to 
CDI   
No 107 132 239 0.098 
Yes 46 37 83 
Invasive GI procedure 
in 12 weeks preceding 
CDI 
No 113 146 259 0.008 
Yes 40 24 64 
Use of tazocin in eight 
weeks preceding illness 
 No 78 116 194 0.000 
 Yes 62 37 99 
Use of clindamycin in 
eight weeks preceding 
CDI 
No 139 147 286 0.123 
Yes 1 6 7 
Treatment of first 
episode 
Metro 44 101 145 0.000 
Vancomycin 76 31 107 
Metronidazole  
&vancomycin 
16 3 19 
No treatment 3 20 23 
Palliative 10 9 19 
Antibiotics given 8 
weeks prior to CDI 
No 11 20 31 0.184 
Yes 132 137 259 
Presence of cdtB No 119 140 259 0.179 
Yes 23 17 40 
30-day mortality No 124 143 267 0.531 
Yes 25 23 48 
1-year mortality due to 
CDI 
No 129 159 288 0.004 
Yes 20 7 27 
Norovirus co-infection No 48 83 136 0.770 
Yes 4 9 13 
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Table	  4.6	  Binary	  logistic	  regression	  	  	  analysis	  of	  factors	  related	  to	  development	  of	  severe	  
infection	  at	  presentation	  or	  within	  one	  year	  of	  index	  episode	  
Variable p value Odds Ratio 95% CI 
  Lower limit Upper limit 
Charlson co-morbidity 
index (age adjusted) 




1.06    1.25 
Presence of 
immunosuppression 
0.001    3.27 1.58    6.76 
Total no. of antibiotics 
administered 8 weeks 
before index episode 
0.239    1.14 0.92    1.40 
Presence of underlying 
GI pathology 
0.119    1.52 0.90    2.56 
Hospital-associated 
acquisition 
0.790    0.92 0.48    
 
1.74 
Invasive GI procedure in 
12 weeks preceding 
episode 




8 weeks preceding 
episode 
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Table	  4.7	  Bivariate	  analysis	  of	  continuous	  variables	  associated	  with	  death	  due	  to	  CDI	  (as	  listed	  
on	  the	  death	  certificate)	  within	  one	  year	  of	  the	  index	  episode	  
Variable One-year CDI related 
mortality  










Mean SD SE  
Mean 
Age (years) 28   
 





28   
 
5.46    2.65     0.50 298   
 
4.76    3.24      0.19 0.195 





25   
 
1.60    1.29      0.26 270   1.91        1.33 0.081 0.226 
Total number of 
episodes on 
record 
28   1.750        0.928 0.18 299    1.49    1.13     0.065 0.176 
Total number of 
episodes in one 
year of study 
28   
 
1.429       0.634 0.12 299   
 




26    19.9    11.6       2.3 246   
 
12.70    7.45      0.48 0.005 
Serum albumin 
level at onset 
(g/L) 
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Table	  4.8	  Bivariate	  analysis	  of	  categorical	  variables	  associated	  with	  death	  due	  to	  CDI	  (as	  listed	  
on	  the	  death	  certificate)	  within	  one	  year	  of	  the	  index	  episode	  
Variable  Death due to 
CDI within 1 
year of index 
episode N  
No CDI related 
mortality 
within 1 year 
of index 






exact test ) 
Gender Male 9 109 118 0.837 
Female 19 190 209 
Immunosuppression Absent 23 250 273 0.793 
Present 5 49 54 
Place of acquisition CA 11 72 83 0.109 
HA 17 227 244 
Acid suppressants (PPI 
and H2 receptor 
antagonists) 
Given 10 159 169 0.193 
Not given 13 115 128 
Underlying GI pathology Not known to 
be present 
15 165 180 1.000 
Present 13 135 147 
Deletion detected in tcdC Absent 18 235 253 0.013 
Present 10 40 50 
Colonisation with MRSA 
or VRE prior to CDI   
No 19 226 245 0.367 
Yes 9 73 82 
Invasive GI procedure in 
12 weeks prior to CDI 
No 27 238 265 0.039 
Yes 1 61 62 
Use of tazocin in eight 
weeks preceding illness 
 No 18 180 198 0.661 
 Yes 7 92 99 
Use of clindamycin in 
eight weeks preceding 
CDI 
No 25 265 290 1.000 
Yes 0 7 7 
Treatment of first 
episode 
Metro 11 136 147 Likelihood 
ratio chi 





Vancomycin 8 99 107 
Metronidazole 
& vancomycin 
3 14 17 
No treatment 0 22 22 
Palliative 4 20 24 
Antibiotics given 8 
weeks prior to CDI 
No 4 29 33 0.329 
Yes 21 251 272 
Presence of cdtB No 20 145 165 0.014 
Yes 8 30 38 
Ribotype 078 5 22 27 0.088 
Non-078 23 253 276 
Norovirus co-infection No 15 124 139 1.000 
Yes 1 12 13 
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Table	  4.9	  Binary	  regression	  model	  for	  multivariable	  analysis	  of	  factors	  associated	  with	  CDI	  
related	  mortality	  within	  one	  year	  of	  index	  episode	  	  	  	  	  	  	  	  	  	  	  	  
Variable p value Odds Ratio 95% CI 
  Lower limit Upper limit 
Age 0.098    1.03    0.99    1.07 
Presence of cdtB 0.351    2.52    0.36   17.68 
 Presence tcdC deletion 0.408    0.46    0.07    2.89 
GI procedure in 12 
weeks preceding index 
episode 
0.022    0.06    0.00    0.65 
Total leucocyte count 
(cells X109/L) 
0.022    1.06    1.01    1.12 
Serum albumin level at 
onset (g/L) 
0.024    0.91    0.83    0.99 
                                              
4.2.1 Age and Gender 
Patients compared in the severe and non-severe episodes did not differ significantly 
in age and gender. These factors were both different between patients who did or did 
not develop a severe episode of CDI (tables 4.1- 4.6). However, age was significantly 
associated with mortality due to CDI within one year of presentation on bivariate 
analysis (table 4.7). Advancing age has been found to be significantly associated 
with development of CDI, and as a risk factor for mortality. Some ambiguity does 
remain as conflicting results have been reported. A study compared 82 patients who 
survived and 46 patients who died within 30d of CDI and did not find a significant 
difference in age (>75 years) or gender (p value 0.11 for age and 0.93 for gender). 
They did however classify their patients by age stratification >75 years and hence if a 
difference existed in the overall age (including those under 75 years), this would not 
be detected. Conversely an American study compared the 30d mortality due to CDI 
and found age >80years significantly associated with mortality (OR 7.91 95% CI 
3.31–18.89, p value 0.001), however there was no such association with gender. 
These differences are likely to be due to variations in methodology and the way age 
is analysed. Stratification of age is more likely to yield a significant result if end 
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points are determined where the difference exists in the populations, whereas studies 
using age as a continuous variable may miss the correlation (Bloomfield et al., 2012).  
4.2.2 Charlson Comorbidity index 
The Charlson comorbidity index was significantly greater in severe vs. non-severe 
episodes as well as in the patients who developed severe disease vs. those who did 
not (table 4.1, 4.3, 4.4, 4.6). This association was statistically significant in the 
multivariable analyses. However there was no difference observed between the CCI 
of patients who died due to CDI compared to those whose death certificates did not 
include CDI  (table 4.7). A German study analysed factors likely to predict severe 
CDI (defined as profuse diarrhoea associated with a heart rate beats pm/systolic 
blood pressure mmHg >1.5 at initial diagnosis) and concluded that CCI was 
independently associated with the risk (p<0.05, OR 1.29; 95% CI 1.02-1.61) along 
with C-reactive protein (Hardt et al., 2008).   Other studies, which have used the 
CCI, have also concluded that it is significantly different between the two groups, 
although the end point used to define severity and the cut-off score used vary 
between the studies (Das et al., 2010, Labbe et al., 2008, Cadena et al., 2010).  
The Charlson score includes various co-morbidities and is generally used as an 
indicator to assess the risk of dying within one year. Since it includes various chronic 
conditions, it is useful as a combination indicator negating the need to assess each 
co-morbidity independently. However, it involves the analysis of 19 different 
parameters and hence its practical application as a routine marker of severity is 
unlikely.   
4.2.3 Antibiotics 
Antibiotics disrupt the normal flora of the gut allowing C. difficile to proliferate and 
cause CDI. In the past, analysis of colonisation factors associated with CDI (S-layer 
proteins, adhesins) has been performed and an up-regulation of these factors 
observed along with increased adhesion to Caco-2/TC7 cells under sub-inhibitory 
concentrations of antibiotics (Deneve et al., 2008).  Other studies have reported a 
complex strain dependent relationship between antibiotics, effects of growth and 
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toxin production (Drummond et al., 2003). However clinical implications of these 
studies are not completely clear.   
In the present study we compared the administration of antibiotics in the 8 weeks 
preceding CDI onset. This factor was found to be statistically significant in the 
bivariate comparison of severe and non-severe episodes and in patients who 
developed severe CDI at onset or within the follow up period compared to those who 
did not (table 4.1, 4.4). However the significance was not continued in the 
multivariable models. In addition, there was no statistical difference between those 
who dies due to CDI compared to those who did not die due to CDI.  The use of 
antibiotics has been studied in the past but an American study (Morrison et al., 2011) 
also did not find a statistical correlation between its use and 30d mortality.  
Each individual antibiotic was also analysed for risk associated with severity but 
only piperacillin-tazobactam (PT) and clindamycin were statistically associated with 
a difference between the severe and non-severe episodes. This association did not 
hold in the multivariable model.  
In addition piperacillin-tazobactam was also different between those who developed 
a severe infection compared to those who did not, its use being more common among 
those who did not develop severe CDI as opposed to those who did (p value 0.000). 
However this association was lost on multivariable analysis (p value 0.239, OR 1.14, 
95% CI 0.92-1.40). Analysis of other antibiotics was difficult due to the small 
numbers involved. Piperacillin-tazobactam has been widely thought of as a relatively 
safe antibiotic with reference to CDI, since compared to third generation 
cephalosporins, it is associated with reduced rates of CDI (Wilcox et al., 2004). 
Though it is known to reduce the number of gut commensals similar to any other 
antibiotic studies in the human gut model have shown that in the presence of 
piperacillin-tazobactam the C. difficile population tended to remain in spores and 
there was no appreciable increase in cytotoxin production (Baines et al., 2005). 
These findings are in keeping with the piperacillin-tazobactam results of the present 
study.  
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4.2.4 Predisposing factors 
4.2.4.1 Total leucocyte count and serum albumin 
These factors were compared between all three compared groups (table 4.1, 4.4 and 
4.7) and were found to be statistically significant in all three. However since they 
were used to define severe disease in this study, they were not entered in the first two 
comparison groups’ multivariable models to avoid creation of bias. They were 
analysed in the multivariable model of death due to CDI within one year and a high 
total leucocyte count and low albumin were correlated with CDI related mortality.  
Previous studies have examined the association of these markers using cut off values 
varying from >15cells X 109/L to >30cells X 109/L for total leucocyte count and 
from <20g/L to <30g/L for albumin, some also having used mean values 
(Dharmarajan et al., 2000, Gujja and Friedenberg, 2009, Andrews et al., 2003, Pepin 
et al., 2007). Although the criteria for outcome varied between the studies, a recent 
meta-analysis found that both these parameters were useful markers of severity to 
determine outcome (Bloomfield et al., 2012). 
4.2.4.2 Invasive GI procedures and underlying GI pathology 
The performance of an invasive GI procedure was significantly associated with the 
development of a severe CDI within the follow up period in the bivariate and 
multivariate models (table 4.5 and 4.6). However there was a negative correlation 
with death due to CDI related causes (table 4.8 and 4.9). The reason for this 
paradoxical phenomenon is not clear but may be due to patients being generally more 
unfit to undergo a GI procedure and hence more likely to die than those who are 
considered fit to undergo GI invasion. It is also possible that this may be a statistical 
artefact due to the low number of patients who died due to CDI.   
4.2.4.3 Immunosuppression 
In the present study, immunosuppression varied significantly between severe and 
non-severe episodes as well as between patients who developed severe infection as 
opposed to those who did not in the bivariate and multivariate analyses (tables 4.2, 
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4.3, 4.5 and 4.6). The significance was however not present in the one-year CDI 
related mortality (table 4.8), possibly due to paucity of numbers.  
The definition of immunosuppression is not standardised and hence varies from 
study to study. For this reason it is difficult to compare directly the results of this 
study with those of others. This may also be a reason why there is heterogeneity in 
the reported significance of immunosuppression as a predictor of severity.   
Liver transplantation has been reported to be associated with a higher odds of 
developing CDI (OR 2.88, 95% CI 2.68-3.10) (Ali et al., 2012). A study examining 
the outcome of CDI in peripheral stem cell transplant recipients did not have enough 
power to define predictive variables (Bilgrami et al., 1999). However, a large study 
comparing three groups of patients with CDI (without steroids), CDI with steroids 
and a non-CDI control arm suggested that the use of any glucocorticoid resulted in 
an increased mortality with a hazard ratio of 2.1+/-0.19 (p<0.001) comparing all 
patients who had CDI. Mortality at 30d was higher in the CDI with steroids group as 
compared to those without steroids (19.3 vs. 9.6%) (Das et al., 2010). Hence it is 
likely that immunosuppression is related to adverse outcome in CDI. This was 
however only partially detected in the present study as presence of 
immunosuppression (which included the use of glucocorticoids in the definition) 
predicted the severity of illness but was not associated with CDI related death. 
4.2.4.4 Hospital associated acquisition and prior colonisation with 
MRSA/VRE 
These factors were not found to be significantly associated in any of the above 
multivariate models. Since the definition of hospital acquisition has only recently 
been standardised, the studies which have examined this variable, have used a variety 
of definitions. This parameter has been discussed in greater detail in chapter five. 
4.2.4.5 Antacids (including PPIs) 
A statistically significant correlation was not found in the use of acid suppressant 
medication and the development of severe CDI in any of the above analyses.  
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4.2.5 Mortality 
The mortality due to CDI was compared between patients who developed a severe 
episode and those who did not. Two outcome measure were used, 30d all cause 
mortality and death due to CDI within one year of CDI. Time to death from first 
episode in the study to death due to CDI ranged from 2-156 days after toxin positive 
result.  Although the 30d mortality was not significantly different between the group 
that developed severe CDI and those who did (p value 0.531), there was a 
statistically significant difference between the CDI specific mortality within one year 
(p value 0.004). However, since 30d mortality by itself is an outcome and not a 
predictor of severe disease, it was not included in the multivariable model. This 
observation is interesting since most authors use 30d all cause mortality as an end 
point for severe CDI rather than CDI specific mortality. It is suggested that CDI 
certification on death is poor, hence the justification in sing 30d all cause mortality.  
The CDI specific mortality was studied further to compare the different variables 
associated with this outcome (table 4.7-4.9). As discussed earlier, the total leucocyte 
count and a low albumin were associated with a statistically significant correlation, 
whereas a GI procedure in 12 weeks preceding CDI was negatively correlated with 
the risk of death due to CDI.  
It may perhaps be of use to pool 30d all cause mortality and all other CDI confirmed 
mortality into one comparator group and perform the above analyses to extract a 
stronger correlation. The figures 4.3 and 4.4 give the distribution of one-year 
mortality and 30d all cause mortality in the present study group.  
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Chapter 5 
Community associated CDI 
5  
5.1 Definitions 
There is considerable variation in the definitions of CDI based on acquisition. 
However, to compare incidence rates and to gauge the efficacy of intervention 
strategies, (McDonald et al., 2007) proposed definitions to enable classification of  
CDI  based on acquisition in the hospital and community setting, from which our 
definitions of hospital associated and community associated are derived.  However, 
their definitions include an indeterminate classification where the symptoms develop 
in the community but there is a past history of admission in a heath care setting 4-12 
weeks prior to the onset of symptoms. These definitions have been used in many 
subsequent studies (Khanna et al., 2012c, Kamboj et al., 2011), albeit with 
modifications. In the present study, the classification used by Khanna et al (2012b) 
was adopted and the following flowchart  (figure 5.1) used to determine whether the 
onset was community associated or hospital associated. 
A total of 250 patients was identified as developing hospital-associated acquisition of 
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Figure	  5.1	  Flowchart	  showing	  the	  division	  of	  patients	  based	  on	  place	  of	  acquisition	  
h/o = history of  
5.2 Association with co-infections 
There is a possibility that diarrhoeal disease presenting in the community could have 
an aetiology different from CDI, although C. difficile toxin was detected in the stool. 
In such a situation it may be difficult to determine the actual cause of the disease. 
The incidence of community associated CDI could potentially be over-reported in 
case there is a substantial number of patients classified as CDI but also possessing 
other pathogens which could be the real cause of the diarrhoea. This is likely since C. 
difficile can be carried asymptomatically in the community whereas other pathogens 
like Salmonella and Norovirus would be less likely to be innocent bystanders.  
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5.2.1 Co-infection with Norovirus 
In the present study 62 patients deemed to have CA-CDI were tested for Norovirus, 
however only one was found to be positive, giving an overall Norovirus co-infection 
rate of 1.2% among all patients with CA-CDI and 1.6% (1/63) among those which 
were tested (see figure 5.2). Comparatively, HA-CDI had a co-infection rate of 4.8% 
among all HA-CDI patients and 13.3% (12/90) among those which were tested and 
the difference was found to be statistically significant (p=0.015)when including the 
whole CA/HA-CDI population or only the tested population as the denominator. 
Although the numbers tested in the hospital were fewer, there was a significant 
proportion, which was found to be positive. This could be explained by the more 
frequent occurrence of Norovirus in the hospital setting as compared to the 
community. However, there are increasing reports of Norovirus occurring in the 
community. In Scotland, in 2010, there were at east two outbreaks of Norovirus, 
which were linked to food, and one was associated with contaminated oysters (HPS, 
2011f). In the first quarter of 2012, there were five outbreaks of Norovirus, which 
occurred in the community (HPS, 2012). Hence community-associated Norovirus, 
though rare, does occur and has been consistently reported. However in this data set, 
there was only one patient who tested positive for Norovirus. This could be because 
patients were included in the study on the basis of C. difficile positivity. If C. difficile 
toxin was not requested on a sample, it may still have had Norovirus present in it, 
which in turn could have had a self limited course and not been tested. On the other it 
may have been tested for Norovirus , but not for CDI. Hence it is possible that a 
careful history taken from the patient can lead to good clinical suspicion of 
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Figure	  5.2	  Patients	  co-­‐infected	  with	  Norovirus.	  	  
 
 
5.2.2 Co-infections with other diarrhoeal pathogens 
All stool samples were tested for bacterial causes of diarrhoea using selective media 
appropriate to travel history. The results are shown in table 5.1 One Campylobacter 
and two gastrointestinal Salmonella infections were found (3.6% bacterial co-
infection rate). In the past, a study from Edinburgh evaluated diarrhoeic patients who 
presented to the infectious disease outpatients department and found that of the 19 
patients from whom C. difficile was cultured, 4 had co-infections with non- typhoid 
Salmonella spp.(Brettle et al., 1982). It would appear that since asymptomatic 
carriage of non-typhoid Salmonella spp in the community is rare, the C. difficile 
could either be a true co-pathogen or asymptomatically carried. More recently, a 
questionnaire-based study of 58 CA-CDI cases reported 8.6% co-infection with 
Campylobacter and Salmonella (three Campylobacter spp. and one Salmonella spp.) 














 Community-associated CDI N=85 Hospital -associated CDI N=250
Slice labels: N,%
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In the present study, patients with co-infections have been included in the statistical 
analysis. In addition, since these were a small proportion of the total sample (3.6% of 
all CA-CDI), the population defined as CA-CDI can be inferred to represents true 
CDI derived from the community 









Campylobacter spp 1(1.2) 3(1.2) 4(1.2) 
Salmonella group B 0 1(0.4) 1(0.3) 
Salmonella group C 1(1.2) 0 1(0.3) 
Salmonella group D 1(1.2) 0 1(0.3) 
Total samples 85 250 335 
 
5.3 Comparison of CA-CDI and HA-CDI 
The variables studied in this project were compared between CA and HA-CDI. The 
comparison of continuous and categorical variables is given in table 5.2 and 5.3. 
Table 5.4 contains the results of multivariate analysis of causative variable found to 
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Table	  	  5.2	  Bivariate	  analysis	  of	  continuous	  variables	  
Analysis done by paired t test  








Mean SD SE  
Mean 
 
Age (years) 85   
 
62.7    23.8       2.6 250   
 





83   
 
3.70    3.38      0.37 250   
 
5.22    3.05      0.19 0.000 
 
Total number of 
different antibiotics 
given in the eight 
weeks preceding  
onset 
74   
 
1.24    1.07      0.12 226   
 
2.09    1.33     0.089 0.000 
 
Total number of 
episodes on record 
85   
 
1.518   0.868     0.094  
250    
 
1.50    1.18     0.074 0.883 
Total leucocyte 
count (cells x109/L) 
53   
 
14.80    9.47       1.3 226   
 
12.93    7.79      0.52 0.186 
Serum albumin 
level at onset (g/L) 
45   
 
31.20    7.39       1.1 174   
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Table	  5.3	  Bivariate	  analysis	  of	  categorical	  variables	  













PCR Ribotype 078 Ribotype 
078 





74(24.1) 233(75.9) 307 
Severity of first 
episode 
Severe 27(18.7) 117(81.3) 144 0.0141 
  Non severe 55(31.3) 121(68.7) 176 
Antacids (PPI and 
H2 receptor 
antagonists) 
Given 38(22.1) 134(77.9) 172 0.417 
  Not given 34(26.2) 96(73.8) 130 
Treatment of first 
episode 








0 19(100) 19 
No abx 
given 
7(29.2) 17(70.8) 24 
Palliative 7(29.2) 17(70.8) 24 




to be present 
51(27.6) 134(72.4) 185 0.315   
Present 24(22.7) 116(77.3) 150 
Inflammatory 
bowel disease 
No 79(25.2) 234(74.8) 313 0.803 
Yes 6(27.4) 16(72.7) 22 
Immunosuppression Absent 77(20.7) 201(72.3) 278 0.031  
  Present 8(14.0) 49(86)) 57 
Colonisation with 
MRSA or VRE 
prior to CDI or 
within follow up 
period 
No 71(28.4) 1179(71.6) 250 0.019   
Yes 13(15.5) 71(84.5) 84 
Major GI procedure 
in 12 weeks prior to 
CDI 
No 81(29.9) 190(70.1) 271 0.000 
  Yes 4(6.3) 60(93.7) 64 
Urban Rural Index Non rural 77(25.8) 221(74.2) 298 0.677 
Rural 7(20.6) 27(79.4) 34 
Death within 30d of 
CDI 
No 69(24.5) 213(75.5) 282 0.392 
Yes 16(30.2) 37(69.8) 53 
Antibiotics given 8 
weeks prior to CDI 
No 20(60.6) 13(39.4) 33 0.000 
Yes 55(19.8) 223(80.2) 278 
Norovirus co-
infection 
No 62(44.3) 78(55.1) 140  0.015 
Yes 1(7.7)) 12(92.3) 13 
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Table	  	  5.4	  Multivariate	  analysis	  of	  causative	  factors	  found	  to	  be	  significantly	  related	  on	  bivariate	  
analysis	  
Predictor variable p value Odds ratio 95% CI 
Lower Upper 
Charlson Comorbidity Index  ( 
age adjusted) 
0.072    1.11 0.99    
 
1.24 
Age 0.109    1.01 1.00    1.03 
Major GI procedure in 12 
weeks prior to CDI 
0.000    7.39 2.44   22.35 
Immunosuppression 0.103    
 
2.39 0.84    
 
6.80 
Colonisation with MRSA or 
VRE prior to CDI or within 
follow up period 
0.201    
 
1.65 0.77    3.57 
Total number of different 
antibiotics given in the eight 
weeks  preceding  onset 
0.000    1.74 1.32    2.29 
*MRSA/VRE colonisation was said to be present if either of these were detected any time prior 
to the development of CDI which could range from 2d to 10 years prior to CDI. 
5.3.1 Age 
Average age (in years) was found to be significantly different between CA- and HA–
CDI (62.7 years vs 67.1 years) on bivariate analysis. Although this difference 
remained apparent on multivariate analysis (OR >1, 95% CI 1, 1.03), the p value was 
no longer significant. This could suggest that the difference in age was small. Other 
studies have suggested that the average age of people presenting with CA-CDI is less 
than those with HA-CDI (Khanna et al., 2012c, Naggie et al., 2010, Naggie et al., 
2011). This could reflect that fact that people admitted in hospital are generally older 
and have more comorbidities than people in the community.  
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5.3.2 Charlson Comorbidity index (CCI) 
On bivariate analysis the mean age adjusted Charlson comorbidity index was found 
to be statistically significant (3.7 vs 5.2 p=0.000) but this difference too appears to 
diminish on multivariate analysis. Similar studies, which have evaluated the CCI, 
have also reported a significant difference (Khanna et al., 2012c, Khanna et al., 
2012b) reflecting the fact that people with more comorbidities are likely to be 
admitted into a health care setting and acquire infection from there whereas healthier 
patients are more likely to acquire infection from the community.  
5.3.3 Antibiotic usage 8 weeks prior to CDI 
The administration of antibiotics in the eight weeks prior to CDI was recorded. In 
patients who were given antibiotics, the total number of different antibiotics given 
was also noted. Both these variables were found to be significantly different in the 
bivariate analysis and retained significance in the multivariate model. A number of 
studies have evaluated the association of antibiotics with CDI (Birgand et al., 2010, 
Wilcox et al., 2004, Wren et al., 2005, Starr et al., 2003).  Interestingly, although 
CDI is often thought to be a disease almost exclusively associated with antibiotics 
use (Wilcox et al., 2004), this assumption has  not been consistently proven. In 
Edinburgh 5 out of 18 patients who presented with CA-CDI did not have any history 
of antibiotics exposure (Brettle and Wallace, 1984, Brettle et al., 1982). More 
recently, systematic studies of CA CDI have also been reported CDI even in the 
absence of antibiotic exposure. In a Veteran’s Affairs Medical Centre only 48% of 
CA-CDI patients had received antibiotics in the preceding 60d prior to symptoms 
(Naggie et al., 2010).  Khanna et al (2012) reported that 22% of patients with CA-
CDI did not have known exposure to antibiotics.  
In this study, details of 20 patients who did not receive antibiotics 8 weeks prior to 
CDI were available. An equal number (six (30%) each) presented with severe and 
non-severe infection and seven were from GP practices and did not have severity 
markers evaluated). Hence it appears that there is a small proportion of patients who 
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present with CDI without any history of antibiotics exposure in the past 8 weeks, 
although they are also at risk of developing severe disease. 
It is also worth considering the contribution of antibiotics given more than 8 weeks 
before CDI. Although this was not evaluated in the present study, recent evidence 
suggests that the effect of antibiotics on the normal flora of the gut may last for 
considerably longer than 8 weeks (Jernberg et al., 2010). 
5.3.4 Association with relapsing and recurrent disease 
In this study, no significant difference was found in the association of community-
associated disease with the occurrence of multiple episodes. The study from 
Minnesota (Khanna et al., 2012c) did not find a significant difference between these 
two groups either (p=0.66). Hence it appears that both CA and HA CDI are equally 
at risk of developing future episodes of CDI. 
5.3.5 Total leucocyte count, serum albumin and severity of infection  
In the present study, total leucocyte counts (TLC) and albumin levels were compared  
between the two group but neither difference was found to be statistically significant. 
However, only 63% and 53% patients of CA-CDI were tested for these markers, 
respectively. Other studies comparing these two categories are lacking, hence useful 
comparisons cannot be made. However, in our study there was a higher proportion of 
severe disease in HA-CDI as opposed to CA-CDI. This may explain why most 
patients presenting from the community were not tested for biochemical and 
haematological markers of severity.  In a comparable study, there was no association 
between community acquisition and lack of severity if patients without 
haematological markers of severity were excluded from analysis. However, on 
including the untested patients (assuming they were not suffering from severe 
disease), there was a significant correlation. More studies with a greater sample size 
may be able to evaluate this association better.  
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5.3.6 PCR ribotype 078 and Urban Rural index 
In the Netherlands, several studies have reported the association of PCR ribotype 078 
with close contact with animals (Hensgens et al., 2012b, Goorhuis et al., 2008b, 
Debast et al., 2009). Other studies have found C. difficile of PCR ribotypes other 
than 078 in the stools of animals (Avbersek et al., 2011, Baverud et al., 1997). Hence 
it is a possibility that disease acquired in the community could be ribotype 078 or 
indeed some other ribotype. We examined the association between community 
acquisition and this ribotype (and ribotype 001) but there was no statistical 
association.  The Urban – rural index differentiates postcodes as belonging to regions 
classified as rural, urban or intermediate. We examined the association of rural and 
non-rural residence with community acquisition with the hypothesis that rural areas 
are more likely to have farm animals (if farm animals predispose to CA-CDI). 
However no significant association was found. In a recent study, the rurality index 
was compared between cases of PCR ribotype 027, 078 and others and no significant 
association was found (Patterson et al., 2012).  The distribution of ribotypes from 
CA-CDI and HA-CDI cases is given in figure 5.3 










































































 PCR Ribotype comparison between CA and HA-CDI
PCR Ribotype
NT: Not typeable  NA: Sample not available 
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5.3.7 Antacids, underlying gastrointestinal pathology and 
inflammatory bowel disease (IBD)  
The difference between CA and HA-CDI was evaluated for use of antacids 
(including proton pump inhibitors and H2 receptor antagonists), pre-existing 
gastrointestinal pathology (including inflammatory bowel disease functional and 
structural abnormalities of the GI tract, bowel carcinoma, other inflammatory 
conditions of the GI tract) and specifically inflammatory bowel disease. None of 
these were significantly different between the two populations.  Most recent studies 
on CA-CDI have examined these factors, and two have found a significant difference 
between acid suppressants given to patients who develop CA-CDI vs those who 
develop HA-CDI (Khanna et al., 2012c, Naggie et al., 2010). However, a later case-
control study by one of these two groups found no significant difference (Naggie et 
al., 2011).  Hence there appears to be no consistent difference in acid suppressive use 
between CA and HA-CDI. This would suggest that patients residing in the 
community are just as likely to develop CDI secondary to acid suppressants as are 
patients admitted in hospitals. Further studies with a careful follow up with adequate 
sample size may be able to consolidate the hypothesis 
5.3.8 GI procedure 3 months prior to CDI and co-infection with MRSA/ 
VRE 
In this study, we compared whether a GI procedure was performed on the patients 
within 3 months of CDI and found a significant difference in both bivariate and 
multivariate models. It is possible that this difference was significant because of the 
underlying association with the definition of CA-CDI, wherein patients with a major 
GI procedure 4 weeks prior to CDI would automatically not be included in the CA 
category. However in spite of this bias, it appears that a GI procedure is likely to 
predispose a patient to develop HA-CDI. This would seem logical since, outpatients 
are less likely to have a GI procedure. Also patients who are admitted in hospital 
with a breach in the structural immunity of the gut in an atmosphere where C. 
difficile is present are more likely to be colonised and subsequently be symptomatic. 
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5.3.9 Treatment of first episode 
The treatment given to patients who develop CA-CDI differed significantly in the 
bivariate analysis. This could be due to the difference in severity between the two 
groups, as Lothian C. difficile  treatment protocols advise that non severe infections 
be treated with oral metronidazole and severe or recurrent infections with oral 
vancomycin with or without metronidazole.  
5.3.10 Immunosuppression 
In the present study, a significant difference was found between the two groups with 
reference to immunosuppressed status and administration of immunosupressants. 
Other studies have not evaluated this factor frequently, however a 2.7% incidence of 
immunosuppression was reported from the South of England (Fellmeth et al., 2010). 
The present study had 14% patients on immunosuppression, which although higher 
than  the quoted study is significantly different from the hospitalised population who 
are in general likely to have a sicker population. 
5.3.11 Death within 30d of CDI 
There was no significant difference found between the likelihood of 30d mortality 
within the two groups in the present study, suggesting that the risk of death within 
30d of CDI is equally likely whether CDI is acquired within the hospital or the 
community. The death certificates of the deceased patients were examined to look for 
the mention of C. difficile as a primary or contributory cause of death. CDI was listed 
on 43.7% death certificates of CA-CDI deaths and 21.6% HA- CDI related deaths. 
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 Chapter 6  
Recurrent disease and analysis of sequential 
isolates 
6  
6.1 Recurrent disease 
6.1.1 Selection of patients 
In this section, an analysis of recurrent disease in the study population is presented.  
A total of 100 patients (29.9%) had more than one episode on record (see figure 6.1) 
and 19.4% experienced more than one episode (recurrence or relapse) in the duration 
of this study (see figure 6.2). Patients who had a documented episode in the past 
(N=35) before the commencement of this study were removed from analysis. In 
addition, since there is a mortality related bias among patients who do not develop 
recurrent disease (they may die before they get a chance to develop recurrence), all 
patients who died within 30d of development of CDI (N=53) were also removed 
from this analysis. An analysis based on removal of patients who died within 14d of 
first CDI was also considered (as used by Eyre et al, 2012), but this would not make 
a difference to the overall statistical inference from the present study as only one 
patient who died between 14 and 30d had developed a recurrent disease. Hence a 
total of 247 patients were included in the statistical analysis of this section (56 
patients who developed more than one episode and 191 patients who had only one 
documented episode). Using this method, we had a recurrence rate of 22.9%. 
Figure 6.3 graphically represents the proportion of patients with recurrent and non-
recurrent CDI who died within 30d of the first episode included in the study (patients 
removed from statistical analysis). 
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Figure	  6.1	  Patients	  with	  multiple	  episodes	  on	  record	  (including	  those	  episodes	  before	  the	  





 No. of patients with more than episode on record
N=335
Slice labels: N, %  





 No. of patients with more than episode in the study period
N=335
Slice labels: N,%  
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Recurrent CDI Non-recurrent CDI
Data not available
Slice labels: N
These patients have been removed from statistical analysis 
6.1.2 Statistical analysis of variables associated with recurrent and 
non-recurrent CDI 
Tables 6.1 and 6.2 contain the bivariate analysis of continuous and categorical 
variables studied in this section. Multivariable analysis was attempted but there were 
insufficient statistically significant variables by bivariate analysis to establish a 
multivariate model. 
6.1.2.1 Summary of results 
Age and serum albumin at presentation were the continuous variables found to be 
statistically different between the groups that developed recurrent and non-recurrent 
disease (p values 0.02 and 0.045 respectively). Charlson co-morbidity index, 
administration of antibiotics eight weeks prior to the first episode and the total 
number of different antibiotics given prior to CDI were also trending towards a 
statistically significant value (p values 0.078, 0.089 and 0.092 respectively).  
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As also seen later in chapter 7, there appears to be a statistically significant 
difference between PCR ribotype 001 and endemic ribotype 078 in the occurrence of 
recurrent disease (p= 0.024). In addition, the one-year CDI related mortality among 
patients who survived the first 30d after CDI is greater in patients with recurrent 
disease than in those who did not develop a second episode.  All other factors studied 
did not appear to have any statistically significant difference. Some of the factors 
found to be significantly associated in the present study and in similar analyses by 
other groups are discussed below.   
6.1.2.2 Comparison with other published studies 
A few studies in the past have analysed recurrent disease and some have tried to 
establish a predictive model for patients likely to develop a recurrent episode (Tal et 
al., 2002, Choi et al., 2011, Eyre et al., 2012, Alfa et al., 1999). These studies are 
discussed in the following sections. 
6.1.2.3 Recurrence rates and risk score 
One of the earlier studies on the topic, a prospective Canadian study by Alfa et al 
(1999), included 75 patients over two and half-year period. This study reported a 
14.7% recurrence rate, which appears to be lower than that reported in the present 
study and others but they followed patients only up to 60d post cure. They did not 
find a statistically significant difference in age or co-morbidities between the 
recurrent and non-recurrent groups (probably due to the low power of the study to 
detect differences). However they did report a difference in duration of hospital 
admission before and after enrolment. Eyre et al (2012) reported a recurrence rate of 
22%. They also examined past heath care exposure and found it significantly 
associated with the risk of developing recurrent CDI. They have included this 
variable in a proposed risk score for recurrent CDI. Unfortunately the present study 
did not evaluate the days before admission as a risk factor for recurrent CDI and may 
be recognised as a limitation of the study. These data are however available and can 
be evaluated at a later date. The effect of hospital or community-associated 
acquisition was however studied but not found to be statistically significant (p value 
0.115 on bivariate analysis) 
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6.1.2.4 Total leucocyte count and serum albumin 
The present study did not find an association between total leucocyte count and 
recurrence, however the albumin levels appeared to be statistically significant (see 
table 6.1). In the study of Choi et al (2012) the white blood cell count, the levels of 
serum albumin, and the levels of C-reactive protein at diagnosis were not 
significantly different between the recurrent and non-recurrent groups.  Eyre et al 
(2012) studied 12 biomarkers in their study group but only higher C-reactive protein 
level and higher neutrophil count at first CDI independently appeared to increase the 
recurrence risk. Unfortunately neither neutrophil nor CRP were recorded in the 
present study. These markers are however available for many patients included in the 
study and can be evaluated at a later date.  
6.1.2.5 Fever and gastric acid suppressing agents 
An Israeli study published in 2002, followed up 43 patients who developed recurrent 
CDI and matched them with 38 patients who did not develop recurrent CDI (Tal et 
al., 2002). They found the use of H2-receptor antagonists a statistically significant 
predictor of recurrent-CDI (p ≤ 0.02), along with faecal incontinence and prolonged 
fever. In the present study, accurate documentation of fever was found to be difficult 
due to the multiple sites involved and hence has not been included in the analysis. 
The use of acid suppressing agents (proton pump inhibitors and H2 receptor 
antagonists) although analysed in the present was not found to be statistically 
different between the two groups (p=0.334). The study of Choi et al (2012) examined 
gastric acid suppression but did not find it significantly associated with recurrence. 
6.1.2.6 Immunosuppression 
Although a study reported recurrent CDI in a patient with allogeneic stem cell 
transplant (Chang et al., 2012) and another has suggested that gastro-intestinal graft 
versus host disease is associated with an increased risk of recurrent CDI (AOR, 4.23; 
95% CI 1.20-14.86; P = 0.02) (Alonso et al., 2012), the lower power in most studies 
does not allow this factor to be studied in details. A recent analysis of 1678 adults 
alive 14 days after their first episode of CDI did not find a statistically significant 
correlation between dialysis or chemotherapy and development of recurrent CDI (RR 
1.15; 95% CI 0.46 – 2.82) (Eyre et al., 2012). Similar to this study, the present study 
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did not find a correlation between immunosuppression and risk of CDI. However 
since the definition of immunosuppression used in all of these studies is different 
from each other, there is still not enough evidence to support or refute the connection 
of immunosuppression with recurrence.  
6.1.2.7 Other hospital-associated pathogens 
Another group from Korea (Choi et al., 2011) evaluated a retrospective cohort of 84 
patients with CDI and reported a recurrence rate of 13.1%, which is substantially 
lower than that reported in the present study and the others discussed earlier. Among 
the factors they studies, enteric colonization with VRE was found to be statistically 
significantly and correlated with the risk of developing recurrent CDI (odds ratio, 
14.519; 95% confidence interval, 1.157-182.229; P = 0.038). The reason for this 
phenomenon is unclear though since VRE and C. difficile are both recognized 
hospital associated pathogens, the co-infection could be due to shared risk factors 
rather than a direct causative role. In the present study, the effect of co-infection with 
VRE and MRSA together was evaluated  (table 6.2) but no statistically significant 
conclusion could be reached. Eyre et al (2012) also studied the effect of prior MRSA 
colonization and it appeared to be a possible factor in the uni-variable analysis but 
they did not find it a statistically significant predictor on the multivariable model (RR 
0.7; 95% CI 0.31 – 1.59; p=0.39).  
6.1.2.8 Association with antibiotics 
In the same study above (Choi et al, 2011) patients who received more than three 
antibiotics were more common in the recurrent group as compared to the non-
recurrent group (63.6% vs 22.4%, p = 0.009) but this association was not found after 
adjusting for confounders.  In the present study administration of antibiotics eight 
weeks prior to CDI and the number of different antibiotics given were both trending 
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Table	  6.1	  Bivariate	  analysis	  of	  continuous	  variables	  compared	  between	  the	  patients	  with	  
recurrent	  and	  non-­‐recurrent	  CDI	  









Mean SD SE  
Mean 
 




56 4.86 2.77 0.37 189 4.11 3.2 0.23 0.089 









49 13.8 7.47 1.1 155 12.21 7.33 0.59 0.198 
Serum albumin 
level at onset 
(g/L) 
35 28.11 5.7 0.97 123 30.49 7.13 0.64 0.045 
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Table	  6.2	  Bivariate	  analysis	  of	  categorical	  patients	  between	  patients	  who	  developed	  recurrent	  
and	  non-­‐recurrent	  CDI	  











exact test ) 
Gender Male 19 67 86 1.000 
Female 37 124 161 
Immunosuppression Present 7 37 4 0.321 
Absent  49 154 203 
Place of acquisition CA 18 42 60 0.155 
HA 38 149 187 
Antacids (PPI and 
H2 receptor 
antagonists) 
Present 31 94 125 0.334 
Absent 19 82 101 
Underlying GI 
pathology 
Present  28 80 108 0.288 
Absent 28 111 139 
Deletion detected in 
tcdC 
Present 6 32 4 0.295 
Absent 48 144 192 
Colonisation with 
MRSA or VRE 
prior to CDI  
Present  12 39 59 0.853 
Absent 44 151 195 
GI invasive 
procedure in 12 
weeks prior to CDI 
Performed 9 47 56 0.207 
Not performed 47 144 191 
Use of tazocin in 
eight weeks 
preceding illness 
Yes 20 54 74 0.234 
No  30 122 152 
Severity of first 
episode 
Non-severe 28 109 137 0.281 
Severe 27 75 102 
Treatment of first 
episode 







4 9 13 
Vancomycin 20 61 81 
No antibiotics 
given 
3 17 20 
Palliative  0 3 3 
Antibiotics given 
eight weeks prior to 
CDI 
Yes 49 156 205 0.078 
No 2 24 26 
Presence of cdtB Present 6 23 29 0.818 
Absent 48 153 201 
Ribotype  001 12 17 29 0.024 
078 2 18 20 
1-year mortality 
due to CDI 
Yes 9 1 10 0.0000087 
No 46 183 229 
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Figure	  6.4	  CDI	  related	  mortality:	  Comparison	  of	  patients	  with	  recurrent	  and	  non-­‐recurrent	  CDI	  
N=335	  	  
Alive/Not dead due to CDI






CDI related mortality at one-year
 
Recurrent CDI Non-recurrent CDI
Data not available
Slice labels: N
 This figure includes patients who died within 30d of diagnosis. However this subgroup was not 
included in the statistical analysis. 
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6.2 Analysis of sequential isolates 










No. of PCR ribotypes detected per patient in separate episodes over 1-year
432 episodes, 335 patients
 
Slice labels: N         
20
 
According to the Department of Health guidelines, a stool sample from an known 
case of CDI is not to be tested again within 28d of the original stool sample (HPA, 
2008), it being considered a continuation of the same episode rather than a fresh one. 
This would however be an assumption that the strain infecting the patient within 28d 
would be the same as the one originally detected.  The purpose of this part of the 
study was to investigate the changes in the strain type over time to determine 
whether the above hypothesis holds true. 
6.2.1 Isolates studied 
One hundred and ninety four isolates from 79 patients were available for PCR 
ribotype analysis of changing epidemiological types. These isolates were stool 
samples obtained from patients collected prospectively during the course of the 
study, as well as those retrieved from stored samples from prior episodes (before the 
onset of this study). Of these, 167 isolates from 67 patients were available for MLVA 
analysis using the seven loci method (six loci for PCR ribotype 078). 
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6.2.2 Differences in PCR ribotype 
Differences in PCR ribotype were observed in 2.3%, 11.11%, 20% and 32.4% 
isolates with time intervals between sampling of 0-20, 21-40, 41-60 and >60days 
respectively, see figure 6.1 















Same PCR ribotype as previous isolate









Changes in PCR ribotype over time
 
Time interval from previous isolate
This chart demonstrates a steady rise in the proportion of isolates, which were different as 
compared to the previous PCR ribotype isolated from the same patient when plotted against 
time. In the column 0-20d there was one isolate at 16d, in column 21-40d there were 3 isolates at 
23, 26 and 27. 
This result suggests that the arbitrary cut off of 28d to call a repeat infection a 
reinfection may be correct in the majority of cases where the PCR ribotype is the 
same, however there are some cases (4 in this study) where there is a different PCR 
ribotype isolated even before 28d. This must be kept in mind if a patient presents 
again with symptoms after a period of recrudescence or if the nature of illness 
changes from mild to severe, since this may be due to a reinfection.  
On the other hand, there are a number of isolates obtained from the same patient 
even after 28d where the PCR ribotype is the same as the previous isolate. This 
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suggests that even though a patient may present with a fresh set of symptoms after 
28d it may be the same episode and hospitals should not be considered liable for this 
new infection if it’s the same strain being carried by the patient. If this new set of 
symptoms occurs in hospital, it is likely to be due to antibiotic usage or due to other 
predisposing factors, which may or may not be modifiable. However PCR ribotyping 
is not the most discriminatory method of epidemiological typing and more 
discriminatory techniques like MLVA or WGS may be needed to differentiate 
between strains. 
An earlier study from 1997 (Wilcox et al., 1998) defined recurrence of C. difficile 
diarrhoea as the resumption of symptoms, after cessation for at least three days, with 
laboratory confirmed cytotoxin positive faeces. They analysed C. difficile isolates by 
RAPD analysis and found 56% of clinical recurrences of infection are in fact due to 
re-infection as opposed to relapse.  
In a study comprising C. difficile isolates from 102 patients with repeat episodes of 
CDI (Kamboj et al., 2011), it was found that in those patients who had a second 
episode within 2-4 weeks of the original episode 90% had the same PCR ribotype, 
those who had a second episode 4-8 weeks apart had the same PCR ribotype in 
86.5% cases and episodes separated by >8 weeks had the same PCR ribotype in 65% 
cases.   Results from our study are roughly comparable with this recent study. 
Another study which compared strains by serotyping from repeat episodes of CDI 
from patients found two different serogroups in 21.5% of patients and to the same 
serogroup in 78.5% of cases. PCR-ribotyping was used to discriminate the latter 
group showed a different pattern in 65.7% of cases. Their results suggest that 45 of 
93 (48.4%) clinical recurrences were in fact due to reinfections with a different 
strain. Delay of relapse and reinfection were a median of 28 and 38 days (Barbut et 
al., 2000). 
Keeping in mind that neither PCR ribotyping nor RAPD are the most discriminatory 
of typing methods (van den Berg et al., 2007); we performed MLVA using 7 loci (6 
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for ribotype 078), to see if there were further differences by using this more 
discriminatory method. 
6.2.3 Differences in MLVA subtype 
Figure	  6.7:	  Temporal	  MLVA	  STRDs	  of	  isolates	  of	  the	  same	  PCR	  ribotype	  compared	  to	  previous	  
isolates	  	  
 
This chart demonstrates differences in MLVA copy numbers of isolates obtained from patients 
with multiple isolates of the same ribotype when plotted against time.  Each point on the graph 
represents the STRD difference between two consecutive isolates from the same patient. All 
isolates were obtained from symptomatic patients and in general those separated by more than 
14d would be separate clinical episodes (recurrences) from the same patient. There appear to be 
large MLVA copy number differences in some isolates temporally close together, whereas 
isolates temporally far apart have fewer differences.  
If each MLVA type were considered a different strain, then going by figure 6.6, it 
would be expected that there be a linear relationship between copy numbers different 
from previous isolates and time from previous isolate. However, this was not 
observed in the analysis (see figure 6.7). It was found that four isolates taken within 
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large copy number differences up to 147d from previous isolate. As time interval 
increased, STRD decreased (although the number of isolates studied was fewer as 
well). 
There can be a number of explanations for this phenomenon. It could be that there 
were a number of different MLVA types infecting the patient and different isolates 
were picked up from different samples. A previous study has shown that 5 of 39 
stool samples had more than one MLVA type (STRD of ≥5) of PCR ribotype 027 
coexisting in one stool sample (Tanner et al., 2010). It could be an explanation for 
the variability seen in our study. However this would not explain why there was a 
larger STRD observed in isolates closer together in time as opposed to those further 
apart. It could be a possibility that since there were fewer isolates, which were 
further apart in time, the difference in STRD could be a sampling bias.  
There is also a possibility that the MLVA technique is flawed and this variation was 
due to technical error. However the technique was validated on known isolates of  
PCR ribotype 001, PCR ribotype 106 and PCR ribotype 002. In addition, it is not a 
very likely possibility since the differing locus of most isolates showing discrepancy 
was repeated twice. MLVA has been shown to be a stable technique by a group, 
which studied serial, isolates from 20 patients and found STRD of ≤	 3 (Marsh et al., 
2006). In another study C. difficile isolates were sub cultured over 10-30 passages 
and found a maximum of one STRD between the first and last isolate (van den Berg 
et al., 2007). Further analysis of these discrepant loci under differing PCR conditions 
may be needed. If the difference persists, whole genome sequencing may reveal 
clues on this phenomenon.  
A later study (Eyre et al., 2012) analysed MLST data from two episodes each of 219  
patients. Making comparisons on the basis of individual sequence types (ST), 169 
(77%) recurrences had the same ST as the initial episode and 50 (23%) represented 
new STs, hence representing new infections. The risk for same-ST recurrence was 
highest at 14 days after the first CDT positive sample, but declined in the next 2–6 
months. Conversely, the risk for new ST infections peaked 30 days after the first CDI 
and then decreased.  However MLST has not been studied in the present study and 
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direct comparisons cannot be made. It would appear however, that these results are in 
keeping with the results from the present study where the risk of infection with the 
same PCR ribotype decreased after 60d from the previous isolate. 
With the results of the present study, it appears that PCR ribotyping is a more robust 
method to study the changing epidemiology within a patient as compared to MLVA, 
since it is more stable and provides rapid answers.  However, if there are  only   a 
few endemic types prevalent in a unit,  PCR ribotyping would be unsuitable due to 
low discrimination.  MLVA appears to be a useful technique to establish 
epidemiological linkages between strains suspected to be part of an outbreak as seen 
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Special features of PCR ribotype 078 
7  
7.1 General epidemiology of infections with PCR 
Ribotype 078 during the study 
PCR Ribotype 078 has been identified in Scotland since 1996 (Taori et al., 2010). 
Subsequently, the incidence has been increasing steadily to 8% of all isolates in 2011 
to the present time, where the Scottish reference laboratory reports a rate of 15% of 
all cases isolated from severe cases and outbreaks from January to March 2012 and 
14% in the periodic surveillance (HPS, 2012).  
In the present study, there were 28 patients (8.4% of total) who had PCR ribotype 
078 identified as the first isolate. Only one of these patients suffered from two 
episodes, all others had a single episode in the one-year follow up period. However 
five other patients (included in the study) had previous episodes of infection, prior to 
the onset of this study. None of the cases patients were epidemiologically related to 
each other so they were considered endemic subtypes. 
During the follow up of this study, an outbreak of PCR ribotype 078 occurred in Jan 
2012. The MLVA subtype of these additional isolates was identical, so these were 
called the outbreak-related isolates. Initially four patients were affected, of who three 
died within four months of diagnosis. One patient survived but remained in hospital 
for a prolonged admission. In July 2012, an increased incidence of CDI was reported 
in a sister hospital where the surviving patient had been admitted for a short period. 
MLVA subtyping revealed three identical and two unrelated strains. Although 
identical by MLVA, these three patients were not directly related in time and space. 
However since they possessed an identical MLVA subtype, these additional cases 
were included in the analysis of the outbreak-related strains to determine whether 
this outbreak–related MLVA subtype was responsible for excessive mortality.  
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7.2 Comparison of cases infected with PCR ribotype 
078, 001 and all other PCR ribotypes  
To establish whether their features were similar to the other infecting PCR ribotypes, 
clinical features of patients infected with PCR ribotype 078 were compared to PCR 
ribotype 001 and all other PCR ribotypes (taken as a group). PCR ribotype 001 has 
been endemic in Lothian for many years (Mutlu et al., 2007, Taori et al., 2010) and 
has been consistently reported in Scotland even though its prevalence has gradually 
decreased from 17% to 10% over 2010 (HPS, 2011a).    Their clinical and 
biochemical variables were compared and the results are given in table 7.1 and 7.2. 
Similarly a comparison of PCR Ribotype 078 with all other non 078, non 001 cases 
was made and the results are given in table 7.3 and 7.4. Multivariable multinominal 
regression analysis of variables which yielded a p value less than 0.05 is given in 
table 7.5. 
Table:	  7.1	  Bivariate	  analysis	  of	  continuous	  variables	  associated	  with	  PCR	  ribotype	  078	  with	  PCR	  
Ribotype	  001	  
Variable PCR ribotype 078 PCR ribotype 001 p 
value N 
 




Mean SD SE  
Mean 




28   4.29    2.71      0.51 44   5.34    2.65      0.40 0.110 
Total number of 
different antibiotics 
given in the eight 
weeks preceding 
onset 
26   1.77    1.48      0.29 41   2.05    1.41      0.22 0.446   
Grand total number 
of episodes 
28   1.250   0.518     0.098 46    2.07    1.90      0.28 0.008   
Total leucocyte 
count (cellsX109/L) 
22    18.6    14.3       3.1 40   13.63    7.75       1.2 0.141 
Serum albumin 
level at onset (g/L) 
17   27.18    8.43       2.0 31   28.48    5.70       1.0 0.573   
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Table:	  7.2	  Bivariate	  analysis	  of	  continuous	  variables	  associated	  with	  PCR	  ribotype	  078	  with	  PCR	  
ribotypes	  non	  078/non	  001	  










Mean SD SE  
Mean 




28      4.29 2.71      0.51 237           4.78 3.39 0.22 0.384   
Total number of 
different antibiotics 
given in the eight 
weeks preceding 
onset 
26     1.77 1.48      0.29 209   1.89    1.29     0.089 0.705   
Grand total number 
of episodes 
28   1.250   0.518     0.098 237   1.422   0.892     0.058 0.137   
Total leucocyte 
count (cellsX109/L) 
22    18.6    14.3       3.1 198   12.63    7.22      0.51 0.066 
Serum albumin 
level at onset (g/L) 









Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
128 
Table:	  7.3	  Bivariate	  analysis	  of	  categorical	  variables	  associated	  with	  PCR	  ribotype	  078	  with	  PCR	  
Ribotype	  001	  	  






001 N (%) 
Total  
N 
p value (Fisher’s 
exact test unless 
specified) 
Gender Male 10 (41.7) 14 (58.3) 24 0.798 
Female 18 (36) 32 (64) 50 





HCA 10 (90.9) 1 (9.1) 11 
CA 11 (47.8) 12 (52.2) 23 
Severity of first 
episode 
Severe 15 (44.1) 9 (55.9) 34  0.343 
Non severe 13 (32.5) 27 (67.5) 40 
Antacids (PPI and 
H2 receptor 
antagonists) 
Given 14 (42.4) 19 (57.6) 33 0.454 
Not given 11 (32.4) 23 (67.5) 34 
Treatment of first 
episode 






3 (37.5) 5 (62.5) 8 
No antibiotics 
given 
1 (550) 1 (50) 2 
Palliative 1 (16.7) 5 (83.3) 6 
Vancomycin 9 (40.9) 13 (59.1) 22 
Underlying GI 
pathology 
Not known to 
be present 
10 (26.3) 28 (73.7) 38 0.054 
Present 18 (50) 18 (50) 36 
Inflammatory 
bowel disease 
No 26 (36.6) 45 (63.4) 71 0.553 
Yes 2 (66.7) 1 (33.3) 3 
Immunosuppression Absent 26 (40) 39 (60) 65 0.468 
Present 2 (22.2) 7 (77.8) 9 
Colonisation with 
MRSA or VRE 
prior to CDI or 
within follow up 
period 
No 23 (43.4) 30 (56.6) 53 0.184 
Yes 5 (25) 15 (75) 20 
GI procedure in 12 
weeks prior to CDI 
No 20 (31.8) 43 (68.3) 63 0.016 
Yes 8 72.7) 3 (27.3) 11 
Urban Rural Index Non rural 23 (35.9) 41 (64.1) 64 0.248 
Rural 5 (62.5) 3 (37.5) 8 
Death within 30d of 
CDI 
No 21 (38.2) 34 (61.8) 55 1.0 
Yes 6 (37.5) 10 (62.5) 16 
Antibiotics given 8 
weeks prior to CDI 
No 3 (33.3) 6 (66.7) 9 1.0 
Yes 23 (37.7) 38 (62.3) 61 
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Table:	  7.4	  Bivariate	  analysis	  of	  categorical	  variables	  associated	  with	  PCR	  ribotype	  078	  with	  non	  
001/non	  078	  PCR	  Ribotypes	  	  















Gender Male 10 (10) 90 (90) 1.0 
Female 18 (10.9) 147 (89.1) 165 







HCA 10 (17.2) 48 (82.8) 58 
CA 11 (16.9) 54 (83.1) 65 
Severity of first 
episode 
Severe 15 (13.2) 99 (86.8) 114 0.423 
Non severe 13 (9.6) 123 (90.4) 136 
Antacids (PPI and H2 
receptor antagonists) 
Given 14 (10) 126 (90) 140 0.831 
Not given 11 (11.1) 88 (88.9) 99 
Treatment of first 
episode 









3 (21.4) 11 (78.6) 14 
No antibiotics 
given 
1 (5) 19 (95) 20 
Palliative 1 (5.9) 16 (94.1) 17 
Vancomycin 9 (10.8) 74 (89.2) 83 
Underlying GI 
pathology 
Not known to be 
present 
10 (7.0) 132 (93) 142 0.07 
Present 18 (14.6) 105 (85.4) 123 
Inflammatory bowel 
disease 
No 26 (10.6) 219 (89.4) 245 1.0 
Yes 2 (10) 18 (90) 20 
Immunosuppression Absent 26 (12.0) 190 (88.0) 216 0.125 
Present 2 (4.1) 47 (95.9) 49 
Colonisation with 
MRSA or VRE prior 
to CDI or within 
follow up period 
No 23 (11.3) 180 (88.7) 203 0.637 
Yes 5 (8.1) 57 (91.9) 62 
GI procedure in 12 
weeks prior to CDI 
No 20 (9.6) 189 (90.4) 209 0.329 
Yes 8 (14.3) 48 (85.7) 56 
Urban Rural Index Non rural 23 (9.8) 212 (90.2) 235 0.209 
Rural 5 (17.2) 24 (82.8) 29 
Death within 30d of 
CDI 
No 21 (9.6) 198 (90.4) 219 0.395 
Yes 6 (15) 34 (85) 40 
Antibiotics given eight 
weeks prior to CDI 
No 3 (12.5) 21 (87.5) 24 0.729 
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Table	  7.5	  Multivariable	  multinominal	  regression	  analysis	  of	  variables	  with	  P	  values	  <0.05	  in	  the	  
bivariate	  analysis.	  PCR	  Ribotype	  078	  set	  as	  baseline	  
Variable PCR Ribotype 078 vs Others PCR Ribotype 078 vs 001 
p 
value 
OR 95% CI p 
value 









Grand total number 
of episodes  




0.86    5.97 0.013    
 




0.986    
 
0.99 0.36    
 
2.71 0.124    
 




HA 0.002    
 
9.80 2.34   41.10 0.005   
 
10.91 2.03   58.69 
HCA 0.826    
 
1.14 0.35    3.74 0.085    
 
0.11 0.01    1.35 
GI procedure in 
preceding 12 weeks 
0.402    
 
0.61 0.19    1.93 0.064    
 
0.16 0.02   1.11 
Age 0.434    
 
0.99 0.96    1.02 0.103    
 
1.03 0.99    1.08 
 
7.2.1  Age 
The comparison between PCR ribotype 078 cases and those with PCR ribotype 001 
revealed a significant difference in the age of the patients between these groups 
(p=0.017), although this difference did not exist when PCR ribotype 078 (median 
71.5 years, range 11-91 years) cases were compared with the non 001/non078 PCR 
ribotypes (median 72 years, range 2-96 years).  On multivariable analysis the 
difference in the former remained but the association was weaker  (OR 1.03, 95% CI 
0.99-1.08) perhaps due to the limited numbers in the study.  A similar study from 
Ireland compared PCR ribotype 078 with PCR ribotype 001 and PCR ribotype 027 
and did not find any significant differences between either of the two groups 
(p=0.96)(Patterson et al., 2012). However another study from the Netherlands had 
earlier found that the population affected by PCR ribotype 078 (N=58) was 
significantly less likely to be older than that infected by PCR ribotype 027 (OR 0.57, 
95% CI 0.33–0.98 for age >85 on multivariate analysis)(Goorhuis et al., 2008a).  
From their study it appears that patients with PCR ribotype 078 are likely to be 
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younger but still among the elderly group (>65years). The results from the present 
study also appear to suggest a similar result, however the comparator group is a 
different PCR ribotype. The present study and the Irish study did not have enough 
numbers to stratify according to age.  
7.2.2 Recurrent/relapsing disease 
When compared to disease caused by PCR ribotype 078, PCR ribotype 001 appeared 
to cause more number of episodes (p=0.013, OR 3.70 95% CI 1.31-10.42 on 
multivariable analysis). However this phenomenon does not exist between PCR 
ribotype 078 and non-078/non 001 PCR ribotypes. Goorhuis et al (2008) found that 
PCR ribotype 027 is likely to cause recurrent disease compared to PCR ribotype 078, 
but their analysis did not include comparison with PCR ribotype 001. Similar to the 
present study, they found no difference in the recurrent disease caused between PCR 
ribotype 078 and other PCR ribotypes taken together. When the first report of an 
Irish outbreak from 2008 came out (Burns et al., 2010), descriptive analysis of the 
outbreak suggested that PCR ribotype 078 in the outbreak caused many more 
recurrences  (46% patients developed recurrent disease) than that suggested in the 
Dutch study (15% recurrence) (Goorhuis et al., 2008a). However, the latter study 
described the characters of the disease in an endemic setting whereas the former were 
observations during an outbreak. 
There could be an alternative reason for the observed difference in the present study. 
It could be that PCR ribotype 078 causes very severe disease and leads to mortality; 
hence the bacterium does not have an opportunity to cause recurrent infection. There 
was no significant difference in the 30d mortality between PCR ribotype 078 and 
PCR ribotype 001 in this study. However further comparing the 30d mortality, 3/10 
(30%) patients who died within 30d with PCR ribotype 001 had CDI listed on the 
death certificate and these had an average Charlson comorbidity index of 2.8. 
Whereas 5/6(83.3%) patients who died within this time with PCR ribotype 078 had 
CDI listed on the death certificate. cause (p=0.12). This latter group had a mean CCI 
of 8.7.  Hence, although the numbers are too small for strong statistical correlation, it 
appears that the patients who died from PCR ribotype 078 within 30d had a lesser 
risk of dying from co-morbidities than the counterparts with PCR ribotype 001. 
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Hence at least in those patients, PCR ribotype 078 caused more severe disease than 
PCR ribotype 001.  
7.2.3 Association with severity and mortality 
Since C. difficile was observed to cause increased mortality in the early 2000s, there 
was a simultaneous increase observed in the presence of PCR ribotype 027. Studies 
have looked into the virulence factors of this type and found that it produces more 
toxin than others in the exponential and stationary phase of growth (Vohra and 
Poxton, 2011a).  
Due to the 38-nucleotide deletion in the tcdC gene of PCR ribotype 078, earlier 
researchers hypothesised that this strain had the potential to cause disease similar to 
PCR ribotype 027 which had an 18bp deletion in tcdC (Goorhuis et al., 2008a, Curry 
et al., 2007, Jhung et al., 2008).  
In this study the severity or 30d mortality caused by endemic PCR ribotype 078 
strains was not found to be significantly different from the disease caused by PCR 
ribotype 001 or other non-078/non 001 PCR ribotypes. There have been mixed 
reports from various groups regarding the association of this PCR ribotype with 
severity. Comparison between studies was difficult because each study used different 
criteria for grading severity. 
In 2008, a hospital-associated outbreak of PCR ribotype 078 occurred in Ireland 
where 15 patients developed CDI due to this PCR ribotype. Of these, four were 
classified as severe using criteria very similar to this study. Eight of these patients 
died of which five (62%) were due to causes directly related to CDI (Burns et al., 
2010). A subsequent systematic case-case study, also from Ireland compared the 
features of PCR ribotype 078 (N=29) with PCR ribotype 001(N=43) and PCR 
ribotype 027(N=42) and found no significant differences in the 30-day mortality 
caused by the former as compared to either of the two latter PCR ribotypes (RRR 
2.94, 95% CI 0.84-10.30 and RRR 1.88, 95% CI 0.49-7.17) respectively (Patterson et 
al., 2012).  
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A group from the Netherlands reported a case series of 13 patients with CDI due to 
PCR ribotype 078. Of these 69% had severe diarrhoea (though the criteria for 
defining severity was not disclosed). Of these two patients died within 30d of 
developing CDI and one death (8%) was attributable to CDI (Goorhuis et al., 2008b). 
The same group in a later publication compared 1687 patients (of which 9% were 
PCR ribotype 078) for severity, recurrence, hospital acquisition, mortality and 
antibiotic use compared to PCR ribotype 027 and all other PCR ribotypes. No 
significant difference was found in the severity of CDI neither between PCR ribotype 
078 and other PCR ribotypes nor between PCR ribotype 027 and PCR ribotype 078 
(Goorhuis et al., 2008a).  
An American study compared the effect of PCR ribotype 027/078 on severe disease 
and found that although on the initial analysis there appeared to be a correlation (OR 
2.33, CI 1.03, 5.02, p=0.035), this relationship disappeared on multivariate analysis 
when the other 11 covariates were accounted for (OR 0.82, CI 0.07, 10.0, 
p=0.874)(Walk et al., 2012). However their definition of severity was different from 
that used in this study, and included only three criteria (intensive care unit admission, 
interventional surgery, or death within 30 days of diagnosis). In addition, they 
compared PCR ribotypes 078 and PCR ribotype 027 together and there is an 
additional bias, which makes direct comparison with the results of the present study 
difficult. 
Hence although there is suspicion that PCR ribotype 078 may cause severe disease, 
this association has not been proven by any published study so far.  
In addition, in a recent study, the 18-nucleotide deletion in the tcdC of PCR ribotype 
027 was restored and the naturally occurring intact tcdC of strain 630 was deleted 
and then subsequently restored using reverse genetics to determine changes in toxin 
production. However no difference was observed suggesting that a deletion in the 
negative regulator may not affect the production of toxin (Cartman et al., 2012). Also 
observed was the phenomenon that the expression of tcdC does not decrease in the 
stationary phase of growth, hence its functional contribution to toxin suppression is 
doubtful (Vohra and Poxton, 2011a). 
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In whole genome analysis experiments of virulent strains of PCR ribotype 027 and 
PCR ribotype 078, gene inserts have been revealed in addition to virulence factors 
which can also be found in related PCR ribotypes (Knetsch et al., 2011). Analysis of 
the clinical features related to these genetically distinct strains might reveal genetic 
markers of severity. 
7.2.4 Association with community acquisition 
In the present study, PCR ribotype 001 and other non-078/non 001 PCR ribotypes 
were more likely to be hospital associated than the endemic cases of PCR ribotype 
078 on multivariable analysis (p=0.002   OR 9.80 95% CI 2.34-41.10 for PCR 
ribotype 078 vs others and p=0.005 OR 10.9 955 CI 2.03-58.69 for PCR ribotype 
078 vs PCR ribotype 001; see table 7.2, 7.4 and 7.5).  In the previously quoted study 
from Ireland (Patterson et al., 2012)  a higher risk of community acquisition was 
reported for patients infected with PCR ribotype 078 compared to PCR ribotype 001 
or PCR ribotype 027 (risk was 96% and 62% higher respectively for community 
compared with inpatient specimens : RRR 1.62; 95% CI: 0.53-4.97; and RRR 1.96; 
95% CI: 0.62-6.18, respectively).  
It is interesting to note that all studies that have compared the acquisition of PCR 
ribotype 078 have linked it to community sources.  The question remains where CA-
CDI is acquired. A suggested hypothesis is that humans acquire it from animals and 
animal products in addition to other vegetable products like salads. The association 
with animals was suggested by the isolation of PCR Ribotype 027 from a dog 
following a visit to the hospital (Lefebvre et al., 2006). In addition, MLVA analysis 
of 11 porcine and 21 human isolates of PCR Ribotype 078 isolates from the 
Netherlands suggested they were genetically related and revealed a clonal complex 
which contains both porcine and human isolates (Debast et al., 2009). This suggests 
that there are sources in the community, which may serve as a reservoir from which 
humans can acquire infection. However, till date no study has been able to irrefutably 
define the relationship between CDI due to PCR ribotype 078 and its acquisition 
from community sources like animals or animal products (Bakri et al., 2009b, 
Hopman et al., 2011a). In addition since other PCR ribotypes like PCR ribotype 027 
and PCR ribotype 015 (Rodriguez-Palacios et al., 2006, Songer et al., 2009, Hopman 
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et al., 2011b) have also been found in animals and meat products, the significance of 
its presence in animals appears to be of zoonotic acquisition as an additional mode of 
infection in general rather than specifically related to PCR ribotype 078. 
Clinical epidemiological analysis of the 2008 Irish outbreak of PCR ribotype 078 
suggested that most patients had contact with either a hospital or a nursing home, 
however on molecular analysis a few clones were discovered where the origin could 
not be established (Burns et al., 2010). This finding suggests that molecular analysis 
along with careful history taking is needed to define the relationship with community 
acquisition. 
7.2.5 GI surgical procedure in 12 weeks prior to CDI and underlying GI 
pathology 
Although there appears to be a link between handling of the GI tract (GI surgical 
procedure) in 12 weeks prior to the development of CDI, this association reached 
statistical significance only in the bivariate analysis suggesting that PCR Ribotype 
078 infections have a greater chance of being preceded by a GI procedure. This 
correlation was lost in the multivariable analysis suggesting that it could be a 
confounded by other factors or the sample size was too small to make conclusions. 
However it would be interesting to study further whether this PCR ribotype has an 
affinity for damaged GI tract. No other study appears to have analysed this factor 
although comparisons with digestive diseases and malignancy in general are 
available (Goorhuis et al., 2008a). Similarly, the presence of an underlying GI 
disease was trending towards significance (p=0.06) but this trend further diminished 
in the multivariate analysis.  
 
7.3 Endemic and outbreak-related isolates:  
Variation within isolates of PCR ribotype 078 
As reported in section 2.1, there were 28 endemic isolates from the original study 
and six outbreak-related strains. The latter appeared to have characteristics 
suggestive of more severe and recurrent disease as opposed to the PCR ribotype 078 
seen in the endemic setting. 
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Since there were only six outbreak-related strains, there was insufficient numbers to 
perform statistical tests of significance. These were however attempted, but none of 
the variables tested reached statistical significance. Hence a descriptive analysis of 
the endemic and outbreak-related strains is given in the following figures (figures 
7.1-7.12). 
Figure	  7.1	  Box	  plot	  of	  age	  distribution	  of	  patients	  infected	  with	  endemic	  and	  outbreak-­‐related	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Figure	  7.3	  Box	  plot	  of	  total	  leucocyte	  count	  and	  serum	  albumin	  observed	  among	  patients	  infected	  
with	  endemic	  and	  outbreak-­‐related	  strains	  of	  PCR	  ribotype	  078.	  











Endemic and Outbreak -related strains of PCR Ribotype 078
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Figure	  7.4	  Box	  plot	  of	  number	  of	  episodes	  per	  patient	  and	  the	  age	  adjusted	  Charlson	  comorbidity	  
index	  of	  endemic	  and	  outbreak-­‐related	  strains	  of	  PCR	  ribotype	  078.	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Figure	  7.6	  Comparison	  of	  location	  of	  acquisition	  between	  endemic	  and	  outbreak-­‐related	  strains	  of	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Figure	  7.8	  GI	  procedures	  performed	  on	  patients	  infected	  with	  of	  endemic	  and	  outbreak-­‐related	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  Figure	  7.10	  Death	  within	  30	  d	  of	  diagnosis	  in	  patients	  infected	  with	  of	  endemic	  and	  outbreak-­‐

















Endemic and Outbreak-related strains of PCR ribotype 078
Death within 30d of diagnosis
Percent within levels 
  
Figure	  7.11	  Comparison	  of	  outcome	  and	  cause	  of	  death	  in	  patients	  infected	  with	  of	  endemic	  and	  
outbreak-­‐related	  strains	  of	  PCR	  ribotype	  078
 
Endemic-078 Outbreak-078 Alive at 1 year
CDI contributary cause













Outcome and cause of death as listed on death certificate
Slice labels: %
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7.3.1 Severity, recurrence and mortality associated with endemic and 
outbreak-related strains of PCR ribotype 078 
In this study the comparison between the endemic and outbreak-related strains of 
PCR ribotype 078 suggests that the outbreak-related strains may cause more severe 
disease compared to the endemic PCR ribotype 078 isolates (66.7% vs 53.6% see 
figure 7.5). In addition, analysis of the mortality data suggests that 33.3% patients in 
the former group died within 30d of CDI whereas 21.4% of the latter suffered early 
mortality. A further detailed examination of all the patients among the former group 
suggests that 71% of infected were still alive at the end of the one year follow up 
period. This is in direct contrast to the outbreak group among which only 33.3% 
were alive even before a one-year follow up was completed. However, the patients in 
the outbreak group did have a higher Charlson co-morbidity index and hence were 
more likely to die due to co-morbidities. In addition, the death certificate information 
revealed that that CDI had contributed to the death of 50% of all patients infected 
with the outbreak-related strain whereas 17.8% of those infected with the endemic 
strains died of CDI. Figure 7.4 also suggests that the outbreak-related strains cause 
more recurrent disease (1.5 episodes /patients) than the endemic strains (only 6/28 
patients developed recurrent disease).  
Comparing the location of acquisition, by definition the outbreak related strains are 
more likely to be hospital associated (83.3%) as opposed to the endemic strains 
(60.7%). It is interesting to note that one of the patients who acquired the outbreak 
associated strain resided in a nursing home and did not have any apparent contact 
with the hospital where these outbreak-related cases occurred. This would suggest 
that the particular strain may be found in the community, however this particular 
MLVA type was not found in any of the other 28 isolates, nor in the four isolates 
from the historical collection stored at the MPRL laboratory.  
From the predisposing factors, it appears that the endemic isolates are more likely to 
infect patients who have had a previous GI surgical procedure or have an underlying 
GI pathology. This would suggest that they infect patients whose GI tracts are 
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already compromised in some way whereas the outbreak strains, perhaps more 
virulent are likely to infect those even without this GI compromise. 
The above information suggests that there may be differences in virulence factors 
between the endemic strains and the outbreak-related strain, which could account for 
the observed difference in mortality. However the numbers in the present study were 
too small to make a definitive conclusion.  
Although the factors responsible for this observation are not clear, a recent study 
(Corver et al., 2012) that analysed the genome of 173 human isolates and  58 porcine 
isolates of PCR ribotype 078 for the presence of Tn6164 (a transposable genetic 
element associated with tetracycline resistance) and found that 18 of these strains 
contained this element. However, clinical details of many patients were unavailable, 
hence association with clinical severity could not be established. In the present study, 
the presence of Tn6164 has not been tested but since the clinical details of all 078 
isolates are available, if this is done in the future valuable information may be 
obtained. 
The above study (Corver et al., 2012) also examined the genomes of 67 other PCR 
ribotypes for this Tn6164 insertion element and did not find it in any of them. This 
suggests that the genome of PCR ribotype 078 is different from others and this may 
have implications in the difference in clinical presentation.  
Till the time of writing, literature search of the English language did not reveal any 
study comparing endemic strains with outbreak related strains of PCR ribotype 078.  
In a non-epidemic setting, comparing a set of 21 CDI patients with varying degrees 
of severity, a study found that although PCR ribotype 027 produced more toxin than 
other PCR ribotypes, there was no association between severity and clinical outcome 
between PCR ribotype 027 and non-027 PCR ribotypes (Sirard et al., 2011). Another 
study from Brighton (UK) analysed 128 patients with CDI in a non-epidemic setting. 
They compared detailed predisposing factors and epidemiological types with 
outcome and found that there does not seem to be an association between PCR 
ribotype and severity. However they did find a correlation between mortality due to 
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CDI and co-morbid conditions like ischaemic heart disease (OR 3.88, 95% CI, 1.61, 
9.37; P=0.003) hypoalbuminemia (OR 3.13, 95% CI, 1.26, 7.75; P=0.014) and renal 
impairment (Wilson et al., 2010). 
In addition, comparing CDI cases in an endemic setting, a study found that the risk 
factors in anoutbreak situation are different from the endemic risk factors (Hensgens 
et al., 2011). Molecular comparison of the virulence factors between the endemic and 
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The above two maps show the geographical location of the residence of 
patients infected with PCR ribotype 078 in the study. Included are the 
outbreak–related strains (shaded in blue). The second picture is a zoomed 
view of the first, focussing on Edinburgh. 
 
7.4 Molecular features   
All isolates of PCR ribotype 078 had toxin genes tcdA, tcdB, cdtA (binary toxin) and 
possessed a 39–base pair deletion in the binding component of toxin regulator gene 
tcdC.  
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When the January outbreak of PCR ribotype 078 was first discovered, the patients 
were located in different wards. Since the time period between the cases ranged from 
3-12 days, a question was raised whether the patients could have carried these 
isolates asymptomatically from the community and developed disease within the 
health care setting as a consequence of antimicrobial therapy and other comorbidity 
factors. This factor may be more relevant since PCR ribotype 078 is known to be 
community associated (Goorhuis et al., 2008a, Patterson et al., 2012) and no other 
outbreak with this PCR ribotype had ever been reported in the past. If true, this 
would absolve the heath care institute from inflicting a hospital acquired infection to 
the affected patients.  
PCR-ribotyping is comparatively a simpler procedure compared to subtyping and the 
genome of this PCR ribotype is known to be difficult to subtype (Bakker et al., 2010) 
because of variations in annealing regions to primers, which will otherwise anneal 
well to other PCR ribotypes. In addition there are some MLVA loci, which are 
absent in this PCR ribotype (though present in other PCR ribotypes). Hence it has 
been difficult to standardize a PCR protocol for MLVA, which will subtype PCR 
ribotype 078 along with other PCR ribotypes. Although some groups have performed 
MLVA for this PCR ribotype successfully (Manzoor et al., 2011), in many  labs it is 
still not routine procedure.  Among the 34 isolates from the present study, 8.8% of 
G8Cd and 11.8% of B7Cd and 38.2% of C6Cd could not be amplified and the lack of 
this data is reflected in the STRDs between strains. However, all loci of the outbreak-
related strains could be amplified.  
The maximum variability was seen in the loci B7Cd  (6-28 copy numbers) and C6Cd 
(11-39 copy numbers).  This study also highlights the importance of subtyping for C. 
difficile isolates. In spite of the limitations mentioned above, the outbreak-related 
strain could be easily differentiated from the other endemic strains and hence the 
technique proved useful in the present study. 
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Figure	  7.13	  Cluster	  analysis	  of	  all	  strains	  of	  PCR	  ribotype	  078	  analysed	  in	  this	  study	  including	  all	  6	  
loci	  tested  
 
Minimum spanning tree (Manhattan) cluster analysis of strains of PCR 
ribotype 078, by 6 locus MLVA. Each node represents a single MLVA profile. 
The circles are labelled with patient numbers (those with the prefix m are 
historical isolates from 1990s and those with prefix ob are outbreak-related 
strains). The numbers between circles are summed tandem repeat differences 
(STRD). Shaded zones indicate related isolates.   Circles numbered A, B and C 
represent more than one isolate. 
No alleles were detected at B7Cd in 5 isolates, at C6Cd in 16 isolates and at 
G8Cd in 4 isolates. 
A= Two isolates from different patients 
B= Two isolates from the same patient and one from an unrelated patient 
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Figure	  7.14:	  Cluster	  analysis	  of	  all	  strains	  of	  PCR	  ribotype	  078	  analysed	  in	  this	  study	  including	  only	  
3	  loci	  (E7Cd	  ,	  CD60	  and	  CD105	  )	  in	  which	  alleles	  were	  detected	  in	  all	  isolate
Minimum spanning tree (Manhattan) cluster analysis of strains of PCR 
ribotype 078, by 3 locus MLVA. Each node represents a single MLVA profile. 
The circles are labelled with letters (index given below). Those with the prefix 
m are historical isolates from 1990s and those with prefix ob are outbreak-
related strains). The numbers between circles are summed tandem repeat 
differences (STRD).  
A= patient no.  1, 121, 123, 137, 215, 228, 246, 264, 292, 295, 323, 325, 64, M140 
B= patient no. 148, 152, 244, 39 
C= patient no. 150, 63, 87 
D= patient no. 257 
E= patient no. 309, 333 
F= patient no. 40 
G= patient number 27, 180 
H= patient no. M145 
I= patient no. M148, M195, M196 
J= patient no. M165 
K= patient no. 80, 95 
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Chapter 8 
Paediatric and neonatal colonisation with 
C.difficile 
8  
8.1 Paediatric nursery (crèche) colonisation 
Parents of 13 children gave consent, of which only two children were found to be 
colonised giving a carriage rate of 15.4%.  
A previous study found C. difficile in only one of 40 neonates during the normal 1-
week stay in the hospital after delivery. Since the mother also carried the same strain, 
as determined by PCR ribotyping, pulsed-field gel electrophoresis analysis, and toxin 
gene type it is assumed that the baby acquired it from the mother.  In addition, the 
same study found a higher (84,4%) carriage rate in infants < 2 years of age.   They 
also found  that several children were colonised with the same type of C. difficile 
which was similar to that found on the floors of the nurseries suggesting  cross-
infection among children and their  environments.(Matsuki et al., 2005). 
However, the carriage rate in our study was too small to make any significant 
deduction.  
8.2 Neonatal colonisation 
 
One hundred and thirty-one stool samples were obtained over a 28-day period from 
30 neonates admitted to the neonatal care ward at the Royal Infirmary of Edinburgh.   
The total number of samples obtained per baby ranged from 1-9. Enrichment cultures 
were initially used to allow growth of scanty C.difficile, if present. However this did 
not give results any different from direct cultures on selective medium, hence 
subsequently only non-selective medium (blood agar) and selective medium (CCEY) 
were used.  Only one positive culture (PCR ribotype 159) was obtained from the last 
sampled stool of a baby who had been in hospital for all the four weeks of the study.  
It is possible that culture is less sensitive than PCR/GDH combination testing and 
Clostridium difficile in south-east Scotland 
 
University of Edinburgh PhD Thesis 2012 
150 
hence the latter would have given a higher positivity rate. Although found in 
symptomatic adults, PCR ribotype 159 is a relatively rare type in the adult population 
(commonest being PCR ribotypes 002, 001, 14, 20 and 15). It was found in one adult 
hospitalized patient in the same period as the neonatal study although no other 
epidemiological link could be established between the two.  
The stool culture results are given in table 8.1 
	  Table	  8.1	  Results	  of	  stool	  C.	  difficile	  carriage	  among	  30	  neonates	  sampled	  over	  a	  four	  weeks	  
Sampling period No of babies 
sampled 
No of babies 
carrying  
C .difficile 
Carriage rate PCR ribotype 
Aug 2010 30 1 3.3% PCR ribotype 
159 
 
This study showed a 3.3% carriage rate in hospitalised neonates. Similar studies have 
demonstrated a carriage rate of up to 71% (Al-Jumaili et al., 1984) . 
Among the early studies, C. difficile was isolated from 28.9% healthy neonates who 
had never received antimicrobials (Viscidi et al., 1981) and C. difficile toxin was 
found in 10.5% of normal newborn infants and 55% of neonates in the intensive care 
unit (Donta and Myers, 1982). 
Our own unit has previously had carriage rates of up to 57% in 1995/96 (see table 
8.2), which was shown to decrease after implementation of infection control 
precautions in the ward. This raises the question whether the implementation of 
modern infection control practices like strict implementation of hand washing, one to 
one nursing and strict control of visitors before entering a ward have contributed to 
the decline in C. difficile acquisition in the neonatal unit of the hospital and whether 
this decline in carriage rate among hospitalized neonates is likely to reduce immunity 
to the disease in adulthood (see bullet-point list below). 
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Table	  8.2	  Results	  of	  previous	  studies	  in	  the	  same	  hospital	  which	  have	  investigated	  
asymptomatic	  colonisation	  
Sampling period No of babies 
sampled 
No of babies 
carrying  
C .difficile 
Carriage rate No of different 
S layer protein 
patterns 
Apr-May 1995 28 16 57% 1 
Aug 1995 19 2 10% 2 
Nov 1995 22 6 27% 5 
Apr-May 1996 30 4 13% 4 
Taffinder, Beal, Shepherd, Laurenson , Brown and Poxton, 1997 see table 8.2 
  
• Restricted entry to the neonatal unit 
• Any person (including staff) entering or leaving the unit are obliged to wash 
their hands with soap and water 
• Any objects brought in from outside are kept away from the babies in a 
separate room.  
• Each baby has a separate cubicle on which only sterilized or objects 
amenable to disinfection are permitted.  
 
However, the parents are encouraged to room in with the babies and mothers are 
encouraged to feed. In spite of this, the measures used to prevent the spread of 
infection are stricter than they would be in a general ward, at a nursery or at home. 
This may be the reason for the low incidence of colonisation. We could not sample 
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the parents and hence transmission to babies from their parents could not be 
determined.  
The sampling method was however biased since the patients studied were all 
neonates who had not had contact with the general population. Most were delivered 
by Caesarian section and hence had no contact with the maternal vaginorectal flora at 
the time of birth. Since the mothers were not studied for C. difficile colonisation, the 
association between maternal and neonatal colonisation cannot be commented upon.   
Implications of early carriage to the immunological development of neonates should 
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Conclusions 
This study has investigated all patients diagnosed with CDI over a period of one 
year. Hence the epidemiology of the entire population served by the Microbiology 
Department of the Royal Infirmary of Edinburgh has been represented.  For this 
reason, it provides a complete picture, which may be missed if only a selected 
population is evaluated.  
The unique characteristics of severe and recurrent disease seen in this region have 
been documented and the effects of potential predisposing factors analysed. This 
study adds to the existing knowledge of these complications of CDI. 
The study of community-associated CDI is very often limited by lack of follow up 
information from community patients. In this study, careful follow up has allowed 
the availability of a complete data set to compare against hospital-associated disease.  
This region of Scotland was unusual in its absence of PCR ribotype 027, but doubts 
persisted whether this PCR ribotype has been missed for lack of ribotyping 
information. This study confirms that this PCR ribotype is not prevalent in this 
region.   
The recent increase in the incidence of PCR ribotype 078 in Scotland has been a 
cause for concern especially since there is gap in the knowledge of the characteristics 
of this  PCR ribotype in this region. This study establishes its link with community 
associated disease and documents the characteristics of the disease caused by it in an 
endemic as well as outbreak situation. Larger studies documenting the characteristics 
of PCR ribotype 078 are needed to determine its potential as a “hypervirulent” strain.  
MLVA as a subtyping technique in research and clinical practice has been studied 
and found useful for establishing epidemiological connections in the presence of an 
outbreak related to PCR ribotype 078.  
Finally, low rates of neonatal and paediatric colonisation with C. difficile as 
compared to previous studies suggest better infection control measures. However 
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they raise concerns on the development of an immune response in these children, 
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Appendix 1 




Date stool sample collected 
Ward/GP requesting the sample 
Date of admission and discharge 
Healthcare contact in past 4 weeks/8 weeks/12 weeks 
 
Present history 
Reason for admission 
Presenting symptoms 
Diarrhoea onset date 
Diarrhoea stopped on 
Fever 
Co-infection with other GI pathogens 
  
Previous history 
Previous CDT positive in past 2 weeks/ 4 weeks/ 8 weeks or longer 
Overnight hospital admission in past 12 weeks 
Antibiotics given in past 8 weeks 
PPIs H2 blockers in past 2 weeks 
Underlying GI pathology, if any 
Previous GI surgery/ endoscopy in past 12 weeks 
Recent travel history 
Recent chemo/radiotherapy 
Prior MRSA/ VRE colonisation on record 
 
Assessment of severity 




Suspected/confirmed pseudomembranous colitis 
Abdominal X-ray results/ colonic dilatation on CT 
Immunosuppression 
ITU admission  
Co-morbidities as per appendix II 
 
Treatment given 
Metronidazole/vancomycin (dose and duration)/ surgery 
Any other: Immunoglobulin etc. 
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Appendix 3 
INFORMATION SHEET (under 12s) 
 
Title of the project:  Clostridium difficile in the neonatal populations: pool of 
potential pathogens and implications for immunity in adulthood 
Your child is being invited to take part in a research study. Please take your time to 
read this information sheet before you agree for him/her take part. Please feel free to 
ask questions if anything is not clear or if you require more information. 
 
1. WHAT IS THE PURPOSE OF THE RESEARCH PROJECT? 
Clostridium difficile is a bacterium that can be found in the bowel without causing 
any harm; however, it can cause diarrhoea in adults, especially after taking 
antibiotics for any reason. However neonates (babies less than 4 weeks old) do not 
develop this disease. 
It is normal for the body to fight infections by producing antibodies and immune 
system cells. Sometimes the body does not produce these antibodies and cells after 
infection by Clostridium difficile and then people can get diarrhoea.  
We are trying to understand why babies are protected against the disease whereas 
adults and older children develop disease. We also want to know which type of C. 
difficile is found in babies. 
2. WHY HAVE WE BEEN CHOSEN? 
 
We need a stool sample and if possible a blood sample (see 4 below) to determine 
which factor(s) protect them from developing disease and to determine if the type of 
C. difficile which is present in the child is the same or different from those in adults.  
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3. DOES MY CHILD HAVE TO TAKE PART? 
It is up to you to decide whether or not to allow your child to take part. 
 
If you decide to consent for your child to take part, you will be given a copy of this 
information sheet and will be asked to sign a consent form. You may withdraw at 
any time without giving a reason. A decision to take part or not will not affect the 
standard of care that your child receives. If you decide to withdraw at any time, this 
will not affect the standard of care that your child receives. 
 
4. WHAT WILL HAPPEN IF I AGREE TO TAKE PART? 
 
If you consent to agree that your child takes part we will take a stool sample and if 
there is any blood left over from routine testing we will use some of this. We will 
analyse your child’s stool for the presence of Clostridium difficile and we will check 
for antibodies to C. difficile in the blood specimen. 
5. WILL MY CHILD NEED TO TAKE ANY DRUGS IF I AGREE FOR HIM 
TO TAKE PART? 
This study does not involve taking any drugs. We will only take a sample of   blood 
and stool.  
 
6. WHAT ARE THE POSSIBLE DISADVANTAGES OF TAKING PART? 
 
There are no risks to your child if you consent for them to take part in this study.  
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7. WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
 
There are no benefits for your child if you decide to take part; however, the results of 
our study could be beneficial for other patients in the future. 
 
8. WHAT HAPPENS WHEN THE RESEARCH STOPS? 
 
We will analyse the data and we will investigate if there is a way of applying our 
results to other patients like your child. After the study is finished, all the samples 
will be destroyed. 
 
9. WILL ANY GENETIC TESTS BE DONE? 
 
No genetic tests will be done. 
 
10. WILL MY CHILD’S PARTICIPATION IN THE RESEARCH PROJECT 
BE KEPT CONFIDENTIAL? 
 
We will note your child’s age, gender and the reason he/she is in hospital. We will 
keep those records anonymous. We will also keep all records confidential. (We will 
inform your GP if you agree to take part in the study). 
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11.  WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH 
STUDY? 
 
The results of the study will be published in scientific journals and presented at 
scientific meetings. You will not be informed of individual test results but can access 
the results of the study by contacting Professor Ian R Poxton (i.r.poxton@ed.ac.uk) 
 
12.  WHO IS ORGANISING AND FUNDING THE RESEARCH? 
 
The study has been organised by the University of Edinburgh Centre for Infectious 
Diseases in collaboration with the Royal Hospital for Sick Children and the 
Microbiology department of Royal Infirmary of Edinburgh. The costs of the research 
will be met from a grant from the Scottish Infection Research Network. 
 
Thank you for taking the time to read this information sheet. 
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                            Appendix 4 
   Stool culture on CCEY after alcohol shock 
 
Take 200 microliter absolute alcohol in a 1.5ml Eppendorf tube 
Mix 200 microlitre or one large loopful stool sample   with the alcohol 
Briefly vortex 
Let the alcohol mix with the stool at room temperature for 10min 
Plate one loopful of diluted stool onto pre-reduced CCEY agar 
 
